

Alberta Human Services Drug Benefit Supplement

Effective April 1, 2020

Alberta  Human Services

Inquiries should be directed to:

Pharmacy Services

Alberta Blue Cross
10009 108 Street NW
Edmonton, AB T5J 3C5

Telephone Number: (780) 498-8370 (Edmonton)
(403) 294-4041 (Calgary)
1-800-361-9632 (Toll Free)

FAX Number: (780) 498-8384
1-877-828-4106 (Toll Free)

Website: <https://www.alberta.ca/alberta-supports.aspx>

Administered by Alberta Blue Cross
on behalf of *Alberta Human Services*.

The Drug Benefit List (DBL) is a list of drugs for which coverage may be provided to program participants. The DBL is not intended to be, and must not be used as a diagnostic or prescribing tool. Inclusion of a drug on the DBL does not mean or imply that the drug is fit or effective for any specific purpose. Prescribing professionals must always use their professional judgment and should refer to product monographs and any applicable practice guidelines when prescribing drugs. The product monograph contains information that may be required for the safe and effective use of the product.

Copies of the *Alberta Human Services Drug Benefit Supplement* are available from Pharmacy Services, Alberta Blue Cross at the address shown above.

Binder and contents: **\$42.00** (\$40.00 + \$2.00 G.S.T.)

Contents only: **\$36.75** (\$35.00 + \$1.75 G.S.T.)

A cheque or money order must accompany the request for copies.

Table of Contents

PART 1

SECTION 1—POLICIES AND GUIDELINES

Introduction

Eligibility	1.1
Additional Notes Regarding Application of the <i>Supplement</i>	1.1
Interchangeable Drug Products	1.1

Restricted Benefits

Restricted Benefits	1.2
---------------------------	-----

Special Authorization Guidelines

Special Authorization Policy	1.3
Special Authorization Procedures	1A.1

SECTION 2—PRICE POLICY

Price Policy

Price Policy	2.1
Additional Units of Issue for Pricing	2.1
Excluded Drug Products	2.1

SECTION 3—CRITERIA FOR SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS

Special Authorization Policy	3.1
Criteria for Coverage	3.2

SECTION 3A— CRITERIA FOR OPTIONAL SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS

Criteria for Optional Special Authorization of Select Drug Products	3A
Criteria for Coverage	3A
Role of the Prescribers	3A

SECTION 4—RARE DISEASES DRUG COVERAGE PROGRAM

Rare Diseases Drug Coverage	4.1
Contraindications	4.1
Rare Diseases Drugs Eligible for Coverage	4.2
Alberta Rare Diseases Clinical Review Panel	4.2
Process for Rare Diseases Drug Coverage	4.2

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

Table of Contents, continued

PART 2

Pharmacologic–Therapeutic Classification of Drugs

00:00	Non-Classified Drugs	1
02:00	Pediatric Cough and Cold Preparations.....	1
04:00	Antihistamine Drugs	1
08:00	Anti-Infective Agents	2
12:00	Autonomic Drugs.....	2
20:00	Blood Formation, Coagulation and Thrombosis.....	3
28:00	Central Nervous System Agents	3
40:00	Electrolytic, Caloric, and Water Balance	6
52:00	Eye, Ear, Nose and Throat Preparations	7
56:00	Gastrointestinal Drugs.....	8
84:00	Skin and Mucous Membrane Agents	9
88:00	Vitamins.....	11
92:00	Miscellaneous Therapeutic Agents	12

Appendices

Appendix 1	Pharmaceutical Manufacturers	13
Appendix 2	Alphabetical List of Pharmaceutical Products.....	14
Appendix 3	Numerical List by Drug Identification Number.....	18

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

PART 1
SECTION 1
Policies
and
Guidelines

INTRODUCTION

Eligibility

The *Alberta Human Services Drug Benefit Supplement (HSDBS)* defines the drugs and drug products that are covered for Alberta Human Services clients in addition to the drugs and drug products defined in the *Alberta Drug Benefit List* (with certain exclusions).

The *Supplement* was developed to take into consideration the essential needs of clients covered under Alberta Human Services programs.

Additional Notes Regarding Application of the *Supplement*

1. The *Supplement* is not intended to be used as a scientific reference or prescribing guide.
2. Formularies used by hospitals and continuing care facilities are developed independently of the *Supplement*.
3. Drugs are classified according to the Pharmacologic–Therapeutic classifications (PTC) developed by the American Society of Hospital Pharmacists for the purpose of the American Hospital Formulary Service.

Permission to use this system has been granted by the American Society of Hospital Pharmacists. The Society is not responsible for the accuracy of transpositions or excerpts from the original content.

Where necessary, additional PTCs may have been assigned by Alberta Blue Cross to facilitate product location in the *Supplement*.

4. Where appropriate, the *Compendium of Pharmaceuticals and Specialties*, published by the Canadian Pharmaceutical Association, was used as a reference source for the trade name, generic name, manufacturer, strength and dosage form.
The Canadian Pharmacist's Association is not responsible for the accuracy of transpositions or excerpts from the original content.
5. Other reference sources used for the trade name, generic name, manufacturer, strength and dosage form are:
 - completed Drug Identification Number (DIN) notification form
 - Notice of Compliance (NOC)
 - Product Monograph
6. DINs listed reflect current manufacturer information available as of April 1, 2020.

Interchangeable Drug Products

A box containing an X to the left of the DIN or Product Identification Number (PIN) indicates that the product is **not** interchangeable with other products within the category. Refer to Policies and Guidelines Section 1 of the current *Alberta Drug Benefit List* for further information regarding interchangeable drug products.

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

RESTRICTED BENEFITS

Restricted Benefits

Selected drug products in the PTCs listed below are eligible benefits with restrictions in the *Supplement*. For these products a comment is displayed in the *HSDBS* after the ingredient name or specific strength for each restricted drug product. The comment initially states "RESTRICTED BENEFIT" and is followed by an explanation of the restriction. For eligible drug products, please refer to the applicable PTCs in the *HSDBS*.

- 00:00:02 Diabetic Supplies (Blood Glucose Meter)**
- 02:00 Pediatric Cough and Cold Preparations**
- 04:02 Pediatric Antihistamines**
- 12:92 Miscellaneous Autonomic Drugs**
- 20:04.04 Antianemia Drugs
(Iron Preparations)**
- 28:08.04.92 Analgesics and Antipyretics
Nonsteroidal Anti-Inflammatory Agents
(Other Nonsteroidal Anti-Inflammatory Agents)**
- 28:16.08.04 Psychotherapeutic Agents
Antipsychotics
(Atypical Antipsychotics)**
- 56:12 Cathartics & Laxatives**
- 84:04.08.28 Anti-Infectives
Antifungals
(Polyenes)**
- 88:16 Vitamin D**
- 88:28 Multivitamin Preparations**
- 88:28:01 Multivitamin Preparations
(Vitamins & Minerals)**

Example:

LORATADINE

RESTRICTED BENEFIT - This product is a benefit for patients up to 17 years of age inclusive.

1 MG / ML ORAL SYRUP

00002241523 CLARITIN

BIC

\$ 0.0542

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

SPECIAL AUTHORIZATION GUIDELINES

Special Authorization Policy

Drug Products Eligible for Consideration by Special Authorization

Drug products may be considered for coverage by special authorization under one or more of the following circumstances, unless a specific product falls under the criteria for drug products **not** eligible for consideration by special authorization. Please see the end of this section for information regarding drug products not eligible for consideration by special authorization.

1. The drug is covered by Alberta Health and/or Alberta Human Services under specified criteria (listed in the following sections). Drug Products and indications other than those specified are not eligible for consideration by special authorization.
2. The drug is normally covered by another government program or agency for a specific approved clinical condition, but is needed for the treatment of a clinical condition that is not covered by that government program or agency.
3. The drug is required because other drug products listed in the *Alberta Drug Benefit List* or the *Alberta Human Services Drug Benefit Supplement* are contraindicated or inappropriate because of the clinical condition of the patient.
4. The particular brand of drug is considered essential in the care of a patient, where the LCA price policy would otherwise apply. Coverage of a specific brand may be considered where a patient has experienced significant allergic reactions or documented untoward therapeutic effects with alternate brands in an interchangeable grouping. Coverage of a brand name product will **not** be considered in situations where the interchangeable grouping includes a pseudo-generic to the brand name drug.
5. A particular drug product or dosage form of a drug is essential in the care of a patient where the MAC price policy would otherwise apply. Exceptions may occur at the product level. Coverage may be considered only where a patient has experienced significant allergic reactions or documented untoward therapeutic effects with the drug product which establishes the MAC pricing.

Prior approval must be granted by Alberta Blue Cross to ensure coverage by special authorization. For those special authorization requests that are approved, the effective date for authorization is the beginning of the month in which the physician's request is received by Alberta Blue Cross.

Special authorization is granted for a defined period as indicated in each applicable special authorization drug product criteria (the "Approval Period"). If continued treatment is necessary beyond the Approval Period, it is the responsibility of the patient and physician to **re-apply for coverage prior to the expiration date of the Approved Period, unless the Auto-Renewal Process or Step Therapy Approval Process apply** (see below).

Auto-Renewal Process

Selected drug products are eligible for the following auto-renewal process (for eligibility, see the Special Authorization criteria for each drug product).

1. For initial approval, a special authorization request must be submitted. If approval is granted, it will be effective for the Approval Period outlined in the drug product's Special Authorization criteria.
2. As long as the patient has submitted a claim for the drug product within the preceding Approval Period (example: within the preceding 6 months), approval will be automatically renewed for a further Approval Period (example: a further 6 months). There is no need for the prescriber to

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

submit a new request as the automated real-time claims adjudication system will read the patient's claims history to determine if a claim has been made within the preceding Approval Period.

3. If the patient does not make a claim for the drug product during the Approval Period, the approval will lapse and a new special authorization request must be submitted.

Step Therapy Approval Process

Select drug products are eligible for coverage via the step therapy process, outlined below.

1. If the patient has made a claim for the First-Line* drug product(s) within the preceding 12 months, the claim for the step therapy drug will be approved.
2. The automated real-time claims adjudication system will read the patient's claims history to determine if the required First-Line* drug product(s) have been claimed within the preceding 12 months.
3. Subsequent claims for drug product(s) permitted by step therapy will continue to be approved as long as the drug product has been claimed within the preceding 12 months.
4. The regular special authorization approval process will continue to be available for step therapy approvals for those patients whose First-Line* drug claims cannot be adjudicated through the automated real-time claims adjudication system.

* A First-Line drug product includes any drug(s) or drug product(s) that, under the drug product's Special Authorization criteria, are required to be utilized before reimbursement for the drug product is permitted.

Drug Products *Not Eligible* for Consideration by Special Authorization

The following categories of drug products are **not** eligible for special authorization:

1. Drug products **deleted** from the *List* or the *Supplement*.
2. Drug products **not yet reviewed** by Alberta Health and/or Alberta Human Services. This applies to:
 - products where a complete submission has been received from the manufacturer and the product is under review,
 - products where an incomplete submission has been received from the manufacturer, and
 - products where the manufacturer has not made a submission for review.Drug products not yet reviewed may encompass new pharmaceutical products, new strengths of products already listed, reformulated products and new interchangeable (generic) products.
3. Drug products that have **completed the review** process and are **not included** on the *List* or the *Supplement*.
4. Most drugs available through Health Canada's Special Access Program.
5. Drug products when prescribed for cosmetic indications.
6. Nonprescription or over-the-counter drug products are generally not eligible.

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

Special Authorization Procedures

A prescriber's request for special authorization should be directed by mail or FAX to:

Clinical Drug Services
Alberta Blue Cross
10009 108 Street NW
Edmonton, Alberta T5J 3C5

FAX: (780) 498-8384 in Edmonton and area
1-877-828-4106 toll-free fax for all other areas

1. A separate request is required for each patient.
2. For a request for special authorization to be considered, the prescriber (an individual authorized by law to prescribe) must contact Alberta Blue Cross and provide the following information:

Patient Identification

- patient's name, address and card holder's name (if different than the patient's),
- Alberta Blue Cross identification number or coverage number/client number of any other applicable coverage (e.g. Alberta Human Services or Alberta Personal Health number, and
- date of birth.

Prescriber Identification

- name of prescriber (e.g. physician, dentist, or optometrist),
- address,
- telephone number and FAX number (if applicable), and
- professional association registration number (e.g. College of Physicians and Surgeons, Alberta Dental Association, or Alberta College of Optometrists registration number).

Drug Requested

- name, strength and dosage form,
- dosage schedule, and
- proposed duration of therapy.

Reason for the Request

- diagnosis and/or indication for which the drug is being used,
- information regarding previous medications which have been used and the patient's response to therapy where appropriate,
- proposed results of therapy, and
- any additional information that may assist in making a decision on the request for special authorization.

3. Special authorization request forms can be found in *Alberta Drug Benefit List*.

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

SECTION 2

Price Policy

PRICE POLICY

Price Policy

The Price Policy is stated in the *Alberta Drug Benefit List*.

Additional Units of Issue for Pricing

Units of issue for pricing in the *Supplement* are defined in the Policies and Guidelines Section 1 of the *List*. The following are additional units of issue that apply to the *Supplement*.

Dosage Form	Unit of Issue Priced in HSDBS
Buccal Spray.....	Dose
Oral Gum	Piece
Oral Pudding.....	Gram
Rectal Pediatric Enema	Enema
Rectal Pediatric Suppository	Suppository
Topical Cream/Vaginal Cream	Kit
Topical Rinse	Millilitre
Topical Shampoo.....	Millilitre
Vaginal Tablet/Topical Cream	Kit

Excluded Drug Products

Drugs Used in the Treatment of Infertility

All drug products used for the **treatment of infertility** are **excluded** as benefits for Alberta Human Services clients and are **not** eligible for special authorization for this indication.

Other Exclusions from the *ADBL*

The following molecules (all brands, forms, routes, and strengths) in the current *Alberta Drug Benefit List* are **excluded** as benefits for Alberta Human Services clients **unless coverage has been granted through Special Authorization**. (Refer to Section 3 - Criteria for Special Authorization of Select Drug Products of the *Supplement* for more information.)

Generic Description	Strength / Form
almotriptan malate	6.25 mg & 12.5 mg tablet
naratriptan hcl	1 mg & 2.5 mg tablet
rizatriptan benzoate	5 mg & 10 mg disintegrating tablet
rizatriptan benzoate	5 mg & 10 mg tablet
sumatriptan hemisulfate	5 mg/dose & 20 mg/dose nasal unit dose spray
sumatriptan succinate	50 mg & 100 mg tablet
sumatriptan succinate	6 mg/syringe injection
zolmitriptan	2.5 mg dispersible tablet
zolmitriptan	2.5 mg tablet
zolmitriptan	5 mg/dose nasal unit dose spray

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

SECTION 3

Criteria for Special Authorization of Select Drug Products

CRITERIA FOR SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS

The drug products listed in this section may be considered for coverage by special authorization for Alberta Human Services clients.

Special Authorization Policy

Drug Products Eligible for Consideration by Special Authorization

Drug products may be considered for coverage by special authorization under one or more of the following circumstances, unless a specific product falls under the criteria for drug products **not** eligible for consideration by special authorization. Please see the end of this section for information regarding drug products not eligible for consideration by special authorization.

1. The drug is covered by Alberta Health and /or Alberta Human Services under specified criteria (listed in the following sections). Drug Products and indications other than those specified are not eligible for consideration by special authorization.
2. The drug is normally covered by another government program or agency for a specific approved clinical condition, but is needed for the treatment of a clinical condition that is not covered by that government program or agency.
3. The drug is required because other drug products listed in the *Alberta Drug Benefit List* or the *Alberta Human Services Drug Benefit Supplement* are contraindicated or inappropriate because of the clinical condition of the patient.
4. The particular brand of drug is considered essential in the care of a patient, where the LCA price policy would otherwise apply. Coverage of a specific brand may be considered where a patient has experienced significant allergic reactions or documented untoward therapeutic effects with alternate brands in an interchangeable grouping. Coverage of a brand name product will **not** be considered in situations where the interchangeable grouping includes a pseudo-generic to the brand name drug.
5. A particular drug product or dosage form of a drug is essential in the care of a patient where the MAC price policy would otherwise apply. Exceptions may occur at the product level. Coverage may be considered only where a patient has experienced significant allergic reactions or documented untoward therapeutic effects with the drug product which establishes the MAC pricing.

Prior approval must be granted by Alberta Blue Cross to ensure coverage by special authorization. For those special authorization requests that are approved, the effective date for authorization is the beginning of the month in which the physician's request is received by Alberta Blue Cross.

Special authorization is granted for a defined period as indicated in each applicable special authorization drug product criteria (the "Approval Period"). If continued treatment is necessary beyond the Approval Period, it is the responsibility of the patient and physician to **re-apply for coverage prior to the expiration date of the Approved Period, unless the Auto-Renewal Process or Step Therapy Approval Process apply** (see below).

Auto-Renewal Process

Selected drug products are eligible for the following auto-renewal process (for eligibility, see the Special Authorization criteria for each drug product).

1. For initial approval, a special authorization request must be submitted. If approval is granted, it will be effective for the Approval Period outlined in the drug product's Special Authorization criteria

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

**ALBERTA HUMAN SERVICES DRUG BENEFIT SUPPLEMENT
CRITERIA FOR SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS**

2. As long as the patient has submitted a claim for the drug product within the preceding Approval Period (example: within the preceding 6 months), approval will be automatically renewed for a further Approval Period (example: a further 6 months). There is no need for the prescriber to submit a new request as the automated real-time claims adjudication system will read the patient's claims history to determine if a claim has been made within the preceding Approval Period.
3. If the patient does not make a claim for the drug product during the Approval Period, the approval will lapse and a new special authorization request must be submitted.

Step Therapy Approval Process

Select drug products are eligible for coverage via the step therapy process, outlined below.

1. If the patient has made a claim for the First-Line* drug product(s) within the preceding 12 months, the claim for the step therapy drug will be approved.
2. The automated real-time claims adjudication system will read the patient's claims history to determine if the required First-Line* drug product(s) have been claimed within the preceding 12 months.
3. Subsequent claims for drug product(s) permitted by step therapy will continue to be approved as long as the drug product has been claimed within the preceding 12 months.
4. The regular special authorization approval process will continue to be available for step therapy approvals for those patients whose First-Line* drug claims cannot be adjudicated through the automated real-time claims adjudication system.

* A First-Line drug product includes any drug(s) or drug product(s) that, under the drug product's Special Authorization criteria, are required to be utilized before reimbursement for the drug product is permitted.

Drug Products Not Eligible for Consideration by Special Authorization

The following categories of drug products are **not** eligible for special authorization:

1. Drug products **deleted** from the *List* or the *Supplement*.
2. Drug products **not yet reviewed** by Alberta Health and/or Alberta Human Services. This applies to:
 - products where a complete submission has been received from the manufacturer and the product is under review,
 - products where an incomplete submission has been received from the manufacturer, and
 - products where the manufacturer has not made a submission for review.Drug products not yet reviewed may encompass new pharmaceutical products, new strengths of products already listed, reformulated products and new interchangeable (generic) products.
3. Drug products that have **completed the review** process and are **not included** on the *List* or the *Supplement*.
4. Most drugs available through Health Canada's Special Access Program.
5. Drug products when prescribed for cosmetic indications.
6. Nonprescription or over-the-counter drug products are generally not eligible.

Criteria for Coverage

Wording that appears within quotation marks (" ") in this section is the official special authorization criteria. Wording that is not enclosed in quotation marks outlines specific information required to interpret criteria, guidelines for submitting requests and/or information regarding conditions under which coverage cannot be provided.

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

ALBERTA HUMAN SERVICES DRUG BENEFIT SUPPLEMENT
CRITERIA FOR SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS

Products Available through Health Canada's Special Access Program

PEMOLINE

"For the treatment of attention deficit hyperactivity disorder where approval has been provided by Health Canada's Special Access Program."

37.5 MG	ORAL TABLET	
DIN N/A*	CYLERT	ABB
75 MG	ORAL TABLET	
DIN N/A*	CYLERT	ABB

**As Cylert has been withdrawn from market, the DINs are no longer valid. Where authorizations for Cylert have been granted, coverage for this product will be provided under PIN 0000999917.*

Other Products

The remaining drug products in this section are listed alphabetically according to the generic ingredient name of the drug. These products can be found on the following pages.

**ALBERTA HUMAN SERVICES DRUG BENEFIT SUPPLEMENT
CRITERIA FOR SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS**

ALMOTRIPTAN MALATE

"For the treatment of acute migraine attacks in patients where other standard therapy has failed. Special authorization may be granted for 24 months."

Information is required regarding previous medications utilized and the patient's response to therapy.

The following product(s) are eligible for auto-renewal.

6.25 MG (BASE)	ORAL TABLET			
00002398435	MYLAN-ALMOTRIPTAN	MYP	\$	7.0433
12.5 MG (BASE)	ORAL TABLET			
00002466821	ALMOTRIPTAN	SNS	\$	2.3478
00002398443	MYLAN-ALMOTRIPTAN	MYP	\$	2.3478
00002405334	SANDOZ ALMOTRIPTAN	SDZ	\$	2.3478
00002434849	TEVA-ALMOTRIPTAN	TEV	\$	2.3478

INFANT FORMULA

"For use in patients who are unable to tolerate, have failed, or have nutritional requirements which cannot be met with the infant formulas which are unrestricted benefits (listed in PTC 40:20 of the Alberta Human Services Drug Benefit Supplement). Information is required regarding the patient's diagnosis, previous infant formulas utilized and the patient's response to therapy, and/or the nutritional requirement which cannot be met with other infant formulas."

ORAL POWDER

<input checked="" type="checkbox"/>	00000999543	PURAMINO A+	MJO	\$	0.1320
-------------------------------------	-------------	-------------	-----	----	--------

"For use in patients who are unable to tolerate, have failed, or have nutritional requirements which cannot be met with the infant formulas which are unrestricted benefits (listed in PTC 40:20 of the Alberta Human Services Drug Benefit Supplement). Information is required regarding the patient's diagnosis, previous infant formulas utilized and the patient's response to therapy, and/or the nutritional requirement which cannot be met with other infant formulas."

<input checked="" type="checkbox"/>	00000999568	NEOCATE WITH DHA & ARA	NUN	\$	0.1581
-------------------------------------	-------------	------------------------	-----	----	--------

"For use in patients who are unable to tolerate, have failed, or have nutritional requirements which cannot be met with the infant formulas which are unrestricted benefits (listed in PTC 40:20 of the Alberta Human Services Drug Benefit Supplement). Information is required regarding the patient's diagnosis, previous infant formulas utilized and the patient's response to therapy, and/or the nutritional requirement which cannot be met with other infant formulas."

NARATRIPTAN HCL

"For the treatment of acute migraine attacks in patients where other standard therapy has failed. Special authorization may be granted for 24 months."

Information is required regarding previous medications utilized and the patient's response to therapy.

The following product(s) are eligible for auto-renewal.

1 MG (BASE)	ORAL TABLET			
00002314290	TEVA-NARATRIPTAN	TEV	\$	11.9041
00002237820	AMERGE	GSK	\$	15.1256
2.5 MG (BASE)	ORAL TABLET			
00002322323	SANDOZ NARATRIPTAN	SDZ	\$	6.1436
00002314304	TEVA-NARATRIPTAN	TEV	\$	6.1436
00002237821	AMERGE	GSK	\$	15.9429

**ALBERTA HUMAN SERVICES DRUG BENEFIT SUPPLEMENT
CRITERIA FOR SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS**

NUTRITIONAL PRODUCT

For use in patients who are unable to tolerate, have failed, or have nutritional requirements which cannot be met with the nutritional products which are unrestricted benefits (listed in PTC 40:20 of the Alberta Human Services Drug Benefit Supplement).

Information is required regarding the patient's diagnosis, previous nutritional products utilized and the patient's response to therapy, and/or the nutritional requirement which cannot be met with other nutritional products.

ORAL LIQUID

<input checked="" type="checkbox"/>	00000999402	BOOST FRUIT FLAVOURED BEVERAGE	NHN	\$	0.0072
<input checked="" type="checkbox"/>	00000999890	ISOSOURCE 1.0 HP	NHN	\$	0.0084
<input checked="" type="checkbox"/>	00000999886	ISOSOURCE FIBRE 1.0 HP	NHN	\$	0.0086
<input checked="" type="checkbox"/>	00000999416	JEVITY 1.2 CAL	ABN	\$	0.0131
<input checked="" type="checkbox"/>	00000999475	JEVITY 1.5 CAL	ABN	\$	0.0150
<input checked="" type="checkbox"/>	00000999430	TWOCAL HN	ABN	\$	0.0153

ORAL PUDDING

<input checked="" type="checkbox"/>	00000999404	ENSURE	ABN	\$	0.0111
<input checked="" type="checkbox"/>	00000999440	BOOST	NHN	\$	0.0122

NUTRITIONAL PRODUCT (ADULT MEAL REPLACEMENT)

For use in patients who are unable to tolerate, have failed, or have nutritional requirements which cannot be met with the nutritional products which are unrestricted benefits (listed in PTC 40:20 of the Alberta Human Services Drug Benefit Supplement).

Information is required regarding the patient's diagnosis, previous nutritional products utilized and the patient's response to therapy, and/or the nutritional requirement which cannot be met with other nutritional products.

ORAL LIQUID

<input checked="" type="checkbox"/>	00000999427	BOOST HIGH PROTEIN	NHN	\$	0.0072
<input checked="" type="checkbox"/>	00000999934	ENSURE HIGH-PROTEIN	ABN	\$	0.0080

NUTRITIONAL PRODUCT (ADULT)

For use in patients who are unable to tolerate, have failed, or have nutritional requirements which cannot be met with the nutritional products which are unrestricted benefits (listed in PTC 40:20 of the Alberta Human Services Drug Benefit Supplement).

Information is required regarding the patient's diagnosis, previous nutritional products utilized and the patient's response to therapy, and/or the nutritional requirement which cannot be met with other nutritional products.

ORAL LIQUID

<input checked="" type="checkbox"/>	00000999944	PEPTAMEN	NHN	\$	0.0271
<input checked="" type="checkbox"/>	00000999435	PEPTAMEN WITH PREBIO 1	NHN	\$	0.0271
<input checked="" type="checkbox"/>	00000999927	MCT OIL	NHN	\$	0.0367
<input checked="" type="checkbox"/>	00000999421	PEPTAMEN 1.5	NHN	\$	0.0389
<input checked="" type="checkbox"/>	00000999467	PEPTAMEN AF 1.2	NHN	\$	0.0428

ORAL POWDER

<input checked="" type="checkbox"/>	00000999935	SCANDISHAKE	AXC	\$	0.0387
<input checked="" type="checkbox"/>	00000999929	TOLEREX	NHN	\$	0.0488
<input checked="" type="checkbox"/>	00000999444	DUOCAL	NUN	\$	0.0716
<input checked="" type="checkbox"/>	00000999415	BENEPROTEIN	NHN	\$	0.0723
<input checked="" type="checkbox"/>	00000999983	VIVONEX T.E.N.	NHN	\$	0.0817
<input checked="" type="checkbox"/>	00000999405	VIVONEX PLUS	NHN	\$	0.0826

**ALBERTA HUMAN SERVICES DRUG BENEFIT SUPPLEMENT
CRITERIA FOR SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS**

NUTRITIONAL PRODUCT (PEDIATRIC)

For use in patients who are unable to tolerate, have failed, or have nutritional requirements which cannot be met with the nutritional products which are unrestricted benefits (listed in PTC 40:20 of the Alberta Human Services Drug Benefit Supplement).

Information is required regarding the patient's diagnosis, previous nutritional products utilized and the patient's response to therapy, and/or the nutritional requirement which cannot be met with other nutritional products.

ORAL LIQUID

<input checked="" type="checkbox"/>	00000999426	COMPLEAT PEDIATRIC	NHN	\$	0.0102
<input checked="" type="checkbox"/>	00000999434	PEDIASURE PLUS WITH FIBRE	ABN	\$	0.0118
<input checked="" type="checkbox"/>	00000999565	KETOCAL	NUN	\$	0.0258
<input checked="" type="checkbox"/>	00000999408	PEPTAMEN JUNIOR	NHN	\$	0.0271
<input checked="" type="checkbox"/>	00000999391	NEOCATE SPLASH	NUN	\$	0.0303
<input checked="" type="checkbox"/>	00000999553	PEPTAMEN JUNIOR 1.5	NHN	\$	0.0404

ORAL POWDER

<input checked="" type="checkbox"/>	00000999559	MODULEN IBD	NHN	\$	0.0677
<input checked="" type="checkbox"/>	00000999445	KETOCAL	NUN	\$	0.1145
<input checked="" type="checkbox"/>	00000999876	PURAMINO A+ JUNIOR	MJO	\$	0.1288
<input checked="" type="checkbox"/>	00000999447	NEOCATE JUNIOR	NUN	\$	0.1299
<input checked="" type="checkbox"/>	00000999560	NEOCATE JUNIOR WITH FIBRE	NUN	\$	0.1299
<input checked="" type="checkbox"/>	00000999422	VIVONEX PEDIATRIC	NHN	\$	0.1349

NUTRITIONAL PRODUCTS

For use in patients who are unable to tolerate, have failed, or have nutritional requirements which cannot be met with the nutritional products which are unrestricted benefits (listed in PTC 40:20 of the Alberta Human Services Drug Benefit Supplement).

Information is required regarding the patient's diagnosis, previous nutritional products utilized and the patient's response to therapy, and/or the nutritional requirement which cannot be met with other nutritional products.

ORAL LIQUID

<input checked="" type="checkbox"/>	00000999864	KETOVIE 3:1	CAM	\$	0.0242
<input checked="" type="checkbox"/>	00000999866	KETOVIE 4:1	CAM	\$	0.0242
<input checked="" type="checkbox"/>	00000999865	KETOVIE PEPTIDE 4:1	CAM	\$	0.0322

RIZATRIPTAN BENZOATE

"For the treatment of acute migraine attacks in patients where other standard therapy has failed. Special authorization may be granted for 24 months."

Information is required regarding previous medications utilized and the patient's response to therapy.

The following product(s) are eligible for auto-renewal.

5 MG (BASE) ORAL TABLET

00002393468	APO-RIZATRIPTAN	APX	\$	3.7050
00002380455	JAMP-RIZATRIPTAN	JPC	\$	3.7050
00002429233	JAMP-RIZATRIPTAN IR	JPC	\$	3.7050

10 MG (BASE) ORAL TABLET

00002381702	ACT RIZATRIPTAN	APH	\$	3.7050
00002393476	APO-RIZATRIPTAN	APX	\$	3.7050
00002441144	AURO-RIZATRIPTAN	AUR	\$	3.7050
00002380463	JAMP-RIZATRIPTAN	JPC	\$	3.7050
00002429241	JAMP-RIZATRIPTAN IR	JPC	\$	3.7050
00002379678	MAR-RIZATRIPTAN	MAR	\$	3.7050
00002240521	MAXALT	MFC	\$	16.5163

**ALBERTA HUMAN SERVICES DRUG BENEFIT SUPPLEMENT
CRITERIA FOR SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS**

RIZATRIPTAN BENZOATE

5 MG (BASE) ORAL DISINTEGRATING TABLET				
00002483270	ACCEL-RIZATRIPTAN ODT	ACP	\$	2.9633
00002458764	CCP-RIZATRIPTAN ODT	CEL	\$	3.7050
00002465086	JAMP-RIZATRIPTAN ODT	JPC	\$	3.7050
00002462788	MAR-RIZATRIPTAN ODT	MAR	\$	3.7050
00002379198	MYLAN-RIZATRIPTAN ODT	MYP	\$	3.7050
00002436604	NAT-RIZATRIPTAN ODT	NTP	\$	3.7050
00002393360	PMS-RIZATRIPTAN RDT	PMS	\$	3.7050
00002442906	RIZATRIPTAN ODT	SNS	\$	3.7050
00002446111	RIZATRIPTAN ODT	SIV	\$	3.7050
00002351870	SANDOZ RIZATRIPTAN ODT	SDZ	\$	3.7050
00002396661	TEVA-RIZATRIPTAN ODT	TEV	\$	3.7050
00002240518	MAXALT RPD	MFC	\$	16.5163
10 MG (BASE) ORAL DISINTEGRATING TABLET				
00002483289	ACCEL-RIZATRIPTAN ODT	ACP	\$	2.9633
00002458772	CCP-RIZATRIPTAN ODT	CEL	\$	3.7050
00002465094	JAMP-RIZATRIPTAN ODT	JPC	\$	3.7050
00002462796	MAR-RIZATRIPTAN ODT	MAR	\$	3.7050
00002379201	MYLAN-RIZATRIPTAN ODT	MYP	\$	3.7050
00002436612	NAT-RIZATRIPTAN ODT	NTP	\$	3.7050
00002393379	PMS-RIZATRIPTAN RDT	PMS	\$	3.7050
00002442914	RIZATRIPTAN ODT	SNS	\$	3.7050
00002446138	RIZATRIPTAN ODT	SIV	\$	3.7050
00002351889	SANDOZ RIZATRIPTAN ODT	SDZ	\$	3.7050
00002396688	TEVA-RIZATRIPTAN ODT	TEV	\$	3.7050
00002240519	MAXALT RPD	MFC	\$	16.5163

SUMATRIPTAN HEMISULFATE

"For the treatment of acute migraine attacks in patients where other standard therapy has failed. Special authorization may be granted for 24 months."

Information is required regarding previous medications utilized and the patient's response to therapy.

The following product(s) are eligible for auto-renewal.

5 MG / DOSE (BASE)	NASAL UNIT DOSE SPRAY			
00002230418	IMITREX	GSK	\$	15.9450
20 MG / DOSE (BASE)	NASAL UNIT DOSE SPRAY			
00002230420	IMITREX	GSK	\$	16.4050

**ALBERTA HUMAN SERVICES DRUG BENEFIT SUPPLEMENT
CRITERIA FOR SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS**

SUMATRIPTAN SUCCINATE

"For the treatment of acute migraine attacks in patients where other standard therapy has failed. Special authorization may be granted for 24 months."

Information is required regarding previous medications utilized and the patient's response to therapy.

The following product(s) are eligible for auto-renewal.

50 MG (BASE) ORAL TABLET				
00002268388	APO-SUMATRIPTAN	APX	\$	2.7732
00002268914	MYLAN-SUMATRIPTAN	MYP	\$	2.7732
00002256436	PMS-SUMATRIPTAN	PMS	\$	2.7732
00002263025	SANDOZ SUMATRIPTAN	SDZ	\$	2.7732
00002286521	SUMATRIPTAN	SNS	\$	2.7732
00002385570	SUMATRIPTAN DF	SIV	\$	2.7732
00002286823	TEVA-SUMATRIPTAN DF	TEV	\$	2.7732
00002212153	IMITREX DF	GSK	\$	16.1771
100 MG (BASE) ORAL TABLET				
00002268396	APO-SUMATRIPTAN	APX	\$	3.0549
00002268922	MYLAN-SUMATRIPTAN	MYP	\$	3.0549
00002256444	PMS-SUMATRIPTAN	PMS	\$	3.0549
00002263033	SANDOZ SUMATRIPTAN	SDZ	\$	3.0549
00002286548	SUMATRIPTAN	SNS	\$	3.0549
00002385589	SUMATRIPTAN DF	SIV	\$	3.0549
00002239367	TEVA-SUMATRIPTAN	TEV	\$	3.0549
00002286831	TEVA-SUMATRIPTAN DF	TEV	\$	3.0549
00002212161	IMITREX DF	GSK	\$	17.8209
6 MG / SYR (BASE) INJECTION SYRINGE				
00002361698	TARO-SUMATRIPTAN (0.5 ML)	TAR	\$	36.1888
00002212188	IMITREX (0.5 ML)	GSK	\$	48.1450

ZOLMITRIPTAN

"For the treatment of acute migraine attacks in patients where other standard therapy has failed. Special authorization may be granted for 24 months."

Information is required regarding previous medications utilized and the patient's response to therapy.

The following product(s) are eligible for auto-renewal.

2.5 MG ORAL TABLET				
00002458780	CCP-ZOLMITRIPTAN	CEL	\$	3.5375
00002421623	JAMP-ZOLMITRIPTAN	JPC	\$	3.5375
00002419521	MINT-ZOLMITRIPTAN	MPI	\$	3.5375
00002421534	NAT-ZOLMITRIPTAN	NTP	\$	3.5375
00002324229	PMS-ZOLMITRIPTAN	PMS	\$	3.5375
00002362988	SANDOZ ZOLMITRIPTAN	SDZ	\$	3.5375
00002313960	TEVA-ZOLMITRIPTAN	TEV	\$	3.5375
00002238660	ZOMIG	AZC	\$	14.9600
2.5 MG ORAL DISPERSIBLE TABLET				
00002428237	JAMP-ZOLMITRIPTAN ODT	JPC	\$	1.7532
00002428474	SEPTA-ZOLMITRIPTAN-ODT	SEP	\$	1.7532
00002243045	ZOMIG RAPIMELT	AZC	\$	14.9600
5 MG / DOSE NASAL UNIT DOSE SPRAY				
00002248993	ZOMIG	AZC	\$	14.9600

SECTION 3A

Criteria for Optional Special Authorization of Select Drug Products

CRITERIA FOR OPTIONAL SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS

The drug products listed in this section may be considered for coverage by optional special authorization for Alberta Human Services clients.

Criteria for Coverage

Wording that appears within quotation marks (“ ”) in this section is the official Optional Special Authorization Criteria, as recommended by the Alberta Health Expert Committee on Drug Evaluation and Therapeutics, and approved by the Minister of Health. Wording that is not enclosed in quotation marks outlines specific information required to interpret criteria, guidelines for submitting requests and/or information regarding conditions under which coverage cannot be provided.

Role of the Prescribers

In conjunction with the criteria, prescribers have two options by which patients may be eligible for coverage of these select optional special authorization drug products.

- 1) Prescribers can register to be a *designated prescriber*. Registration allows for patients to receive coverage of select drug products **without Special Authorization** as long as the prescription is written for one of the criteria for coverage set out in this section. Should a designated prescriber wish to prescribe one of the select drug products outside the coverage criteria, they may do so but must indicate this on the prescription; however, patients will not be eligible for payment under the Alberta government-sponsored program for such prescription and the patient may choose to receive the product at their expense. The registration form may be found on the previous page.
- 2) Prescribers who choose not to register will be considered *non-designated prescribers*. Such prescribers **will be required to apply for Special Authorization** on the patient's behalf.

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.



ALBERTA GOVERNMENT SPONSORED DRUG BENEFIT PROGRAMS
OPTIONAL SPECIAL AUTHORIZATION

REGISTRATION FOR DESIGNATED PRESCRIBER STATUS
for Alberta Drug Benefit List Claim Coverage

Select Quinolone Antibiotics
ciprofloxacin, levofloxacin, moxifloxacin

Please complete all sections of this form
and return it by fax to Alberta Blue Cross

Registrations will be accepted on an ongoing basis

PRESCRIBER LAST NAME	FIRST NAME	INITIAL	OFFICE PHONE	FAX
OFFICE ADDRESS		CITY	PROVINCE	POSTAL CODE
COLLEGE OF PHYSICIANS AND SURGEONS REGISTRATION NUMBER OR PROFESSIONAL REGISTRATION NUMBER				
I have reviewed the criteria for coverage of select quinolone products and I agree to abide by and only prescribe in accordance with such criteria as updated from time to time in the Optional Special Authorization section of the <i>Alberta Drug Benefit List</i> .				
SIGNATURE OF PRESCRIBER (required) _____			DATE _____	
The information on this form is being collected and pursuant to sections 20, 21 and 22 of the Health Information Act, and sections 33 and 34 of the Freedom of Information and Protection of Privacy Act, for the purposes of determining or verifying eligibility to participate in a program or receive a benefit, product or health service. If you have any questions regarding the collection or use of this information, please contact an Alberta Blue Cross privacy matters representative toll-free at 1-855-498-7302 or write to Privacy Matters, Alberta Blue Cross, 10009 - 108 Street, Edmonton AB T5J 3C5.				

PLEASE RETURN YOUR COMPLETED REGISTRATION BY FAX TO 1-877-305-9911



Criteria For Optional Special Authorization Of Select Drug Products

Patient claims for select quinolone prescriptions written by a non-designated prescriber will be subject to a first forgiveness rule, meaning the first claim will be paid. Subsequent claims for the same product (irrespective of strength, route and form) within a 90-day period would require the prescriber to apply for special authorization for coverage on the patient's behalf.

CIPROFLOXACIN

"For the treatment of:

1) Respiratory Tract Infections:

- end stage COPD with or without bronchiectasis, where there has been documentation of previous *Pseudomonas aeruginosa* colonization/infection or
- pneumonic illness in cystic fibrosis; or

2) Genitourinary Tract Infections:

- urinary tract infections,
- prostatitis,
- prophylaxis of urinary tract surgical procedures or
- gonococcal infections; or

3) Skin and Soft Tissue/Bone and Joint Infections:

- malignant/invasive otitis externa,
- bone/joint infections due to gram negative organisms or
- therapy/step-down therapy of polymicrobial infections in combination with clindamycin or metronidazole e.g. diabetic foot infection, decubitus ulcers; or

4) Gastrointestinal Tract Infections:

- bacterial gastroenteritis where antimicrobial therapy is indicated,
- typhoid fever (enteric fever), or
- therapy/step-down therapy of polymicrobial infections in combination with clindamycin or metronidazole e.g. intra-abdominal infections; or

5) Other:

- prophylaxis of adult contacts of cases of invasive meningococcal disease,
- therapy/step-down therapy of hospital acquired gram negative infections,
- empiric therapy of febrile neutropenia in combination with other appropriate agents or
- exceptional case of allergy or intolerance to all other appropriate therapies as defined by relevant guidelines/references i.e. AMA CPGs or Bugs and Drugs.
- for use in other current Health Canada approved indications when prescribed by a specialist in Infectious Diseases."

All requests for ciprofloxacin must be completed using the Select Quinolones Special Authorization Request Form (ABC 60042).

100 MG / ML ORAL SUSPENSION

00002237514

CIPRO

BAI

\$

0.5750

**ALBERTA HUMAN SERVICES DRUG BENEFIT SUPPLEMENT
CRITERIA FOR OPTIONAL SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS**

CIPROFLOXACIN HCL

"For the treatment of:

1) Respiratory Tract Infections:

- end stage COPD with or without bronchiectasis, where there has been documentation of previous Pseudomonas aeruginosa colonization/infection or
- pneumonic illness in cystic fibrosis; or

2) Genitourinary Tract Infections:

- urinary tract infections,
- prostatitis,
- prophylaxis of urinary tract surgical procedures or
- gonococcal infections; or

3) Skin and Soft Tissue/Bone and Joint Infections:

- malignant/invasive otitis externa,
- bone/joint infections due to gram negative organisms or
- therapy/step-down therapy of polymicrobial infections in combination with clindamycin or metronidazole e.g. diabetic foot infection, decubitus ulcers; or

4) Gastrointestinal Tract Infections:

- bacterial gastroenteritis where antimicrobial therapy is indicated,
- typhoid fever (enteric fever), or
- therapy/step-down therapy of polymicrobial infections in combination with clindamycin or metronidazole e.g. intra-abdominal infections; or

5) Other:

- prophylaxis of adult contacts of cases of invasive meningococcal disease,
- therapy/step-down therapy of hospital acquired gram negative infections,
- empiric therapy of febrile neutropenia in combination with other appropriate agents or
- exceptional case of allergy or intolerance to all other appropriate therapies as defined by relevant guidelines/references i.e. AMA CPGs or Bugs and Drugs.
- for use in other current Health Canada approved indications when prescribed by a specialist in Infectious Diseases."

All requests for ciprofloxacin must be completed using the Select Quinolones Special Authorization Request Form (ABC 60042).

250 MG (BASE) ORAL TABLET

00002247339	ACT CIPROFLOXACIN	APH	\$	0.4454
00002381907	AURO-CIPROFLOXACIN	AUR	\$	0.4454
00002353318	CIPROFLOXACIN	SNS	\$	0.4454
00002386119	CIPROFLOXACIN	SIV	\$	0.4454
00002380358	JAMP-CIPROFLOXACIN	JPC	\$	0.4454
00002379686	MAR-CIPROFLOXACIN	MAR	\$	0.4454
00002423553	MINT-CIPROFLOX	MPI	\$	0.4454
00002248437	PMS-CIPROFLOXACIN	PMS	\$	0.4454
00002303728	RAN-CIPROFLOX	RAN	\$	0.4454
00002248756	SANDOZ CIPROFLOXACIN	SDZ	\$	0.4454

500 MG ORAL TABLET

00002247340	ACT CIPROFLOXACIN	APH	\$	0.5025
00002381923	AURO-CIPROFLOXACIN	AUR	\$	0.5025
00002353326	CIPROFLOXACIN	SNS	\$	0.5025
00002386127	CIPROFLOXACIN	SIV	\$	0.5025
00002380366	JAMP-CIPROFLOXACIN	JPC	\$	0.5025
00002379694	MAR-CIPROFLOXACIN	MAR	\$	0.5025
00002248438	PMS-CIPROFLOXACIN	PMS	\$	0.5025
00002303736	RAN-CIPROFLOX	RAN	\$	0.5025
00002248757	SANDOZ CIPROFLOXACIN	SDZ	\$	0.5025

ALBERTA HUMAN SERVICES DRUG BENEFIT SUPPLEMENT
CRITERIA FOR OPTIONAL SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS

CIPROFLOXACIN HCL

750 MG (BASE) ORAL TABLET

00002247341	ACT CIPROFLOXACIN	APH	\$	0.9201
00002380374	JAMP-CIPROFLOXACIN	JPC	\$	0.9201
00002379708	MAR-CIPROFLOXACIN	MAR	\$	0.9201
00002423588	MINT-CIPROFLOX	MPI	\$	0.9201
00002248439	PMS-CIPROFLOXACIN	PMS	\$	0.9201
00002303744	RAN-CIPROFLOX	RAN	\$	0.9201
00002248758	SANDOZ CIPROFLOXACIN	SDZ	\$	0.9201

ALBERTA HUMAN SERVICES DRUG BENEFIT SUPPLEMENT
CRITERIA FOR OPTIONAL SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS

LEVOFLOXACIN

250 MG ORAL TABLET

00002315424	ACT LEV OFLOXACIN	TEV	\$	1.2038
00002284707	APO-LEV OFLOXACIN	APX	\$	1.2038
00002298635	SANDOZ LEV OFLOXACIN	SDZ	\$	1.2038

"To be prescribed according to ONE of the following criteria:

For the treatment of

- 1) Community acquired pneumonia after failure of first line therapy, as defined by clinical deterioration after 72 hours of antibiotic therapy or lack of improvement after completion of antibiotic therapy; or
- 2) Community acquired pneumonia in patients with co-morbidities (asthma, lung cancer, COPD, diabetes, alcoholism, chronic renal or liver failure, CHF, chronic corticosteroid use, malnutrition or acute weight loss, hospitalization within previous 3 months, HIV/AIDS, smoking); or
- 3) Acute exacerbation of chronic bronchitis after failure of first and second line therapy, as defined by clinical deterioration after 72 hours of antibiotic therapy or lack of improvement after completion of antibiotic therapy; or
- 4) Acute sinusitis after failure of first line therapy, as defined by clinical deterioration after 72 h of antibiotic therapy or lack of improvement after completion of antibiotic therapy, in patients with beta-lactam (penicillin and cephalosporin) allergy; or
- 5) For use in other current Health Canada approved indications when prescribed by a specialist in Infectious Diseases."

All requests for Levofloxacin must be completed using the Select Quinolones Special Authorization Request Form (ABC 60042).

ALBERTA HUMAN SERVICES DRUG BENEFIT SUPPLEMENT
CRITERIA FOR OPTIONAL SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS

LEVOFLOXACIN

500 MG ORAL TABLET

00002315432	ACT LEVOFLOXACIN	TEV	\$	1.3718
00002284715	APO-LEVOFLOXACIN	APX	\$	1.3718
00002298643	SANDOZ LEVOFLOXACIN	SDZ	\$	1.3718

"To be prescribed according to ONE of the following criteria:

For the treatment of

- 1) Community acquired pneumonia after failure of first line therapy, as defined by clinical deterioration after 72 hours of antibiotic therapy or lack of improvement after completion of antibiotic therapy; or
- 2) Community acquired pneumonia in patients with co-morbidities (asthma, lung cancer, COPD, diabetes, alcoholism, chronic renal or liver failure, CHF, chronic corticosteroid use, malnutrition or acute weight loss, hospitalization within previous 3 months, HIV/AIDS, smoking); or
- 3) Acute exacerbation of chronic bronchitis after failure of first and second line therapy, as defined by clinical deterioration after 72 hours of antibiotic therapy or lack of improvement after completion of antibiotic therapy; or
- 4) Acute sinusitis after failure of first line therapy, as defined by clinical deterioration after 72 h of antibiotic therapy or lack of improvement after completion of antibiotic therapy, in patients with beta-lactam (penicillin and cephalosporin) allergy; or
- 5) For use in other current Health Canada approved indications when prescribed by a specialist in Infectious Diseases."

All requests for Levofloxacin must be completed using the Select Quinolones Special Authorization Request Form (ABC 60042).

ALBERTA HUMAN SERVICES DRUG BENEFIT SUPPLEMENT
CRITERIA FOR OPTIONAL SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS

LEVOFLOXACIN

750 MG ORAL TABLET

00002315440	ACT LEV OFLOXACIN	TEV	\$	4.8478
00002325942	APO-LEV OFLOXACIN	APX	\$	4.8478
00002298651	SANDOZ LEV OFLOXACIN	SDZ	\$	4.8478

"To be prescribed according to ONE of the following criteria:

For the treatment of

- 1) Community acquired pneumonia after failure of first line therapy, as defined by clinical deterioration after 72 hours of antibiotic therapy or lack of improvement after completion of antibiotic therapy; or
- 2) Community acquired pneumonia in patients with co-morbidities (asthma, lung cancer, COPD, diabetes, alcoholism, chronic renal or liver failure, CHF, chronic corticosteroid use, malnutrition or acute weight loss, hospitalization within previous 3 months, HIV/AIDS, smoking); or
- 3) Acute exacerbation of chronic bronchitis after failure of first and second line therapy, as defined by clinical deterioration after 72 hours of antibiotic therapy or lack of improvement after completion of antibiotic therapy; or
- 4) Acute sinusitis after failure of first line therapy, as defined by clinical deterioration after 72 h of antibiotic therapy or lack of improvement after completion of antibiotic therapy, in patients with beta-lactam (penicillin and cephalosporin) allergy; or
- 5) For use in other current Health Canada approved indications when prescribed by a specialist in Infectious Diseases."

All requests for Levofloxacin must be completed using the Select Quinolones Special Authorization Request Form (ABC 60042).

**ALBERTA HUMAN SERVICES DRUG BENEFIT SUPPLEMENT
CRITERIA FOR OPTIONAL SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS**

MOXIFLOXACIN HCL

"To be prescribed according to ONE of the following criteria:

For the treatment of

- 1) Community acquired pneumonia after failure of first line therapy, as defined by clinical deterioration after 72 hours of antibiotic therapy or lack of improvement after completion of antibiotic therapy; or
- 2) Community acquired pneumonia in patients with co-morbidities (asthma, lung cancer, COPD, diabetes, alcoholism, chronic renal or liver failure, CHF, chronic corticosteroid use, malnutrition or acute weight loss, hospitalization within previous 3 months, HIV/AIDS, smoking); or
- 3) Acute exacerbation of chronic bronchitis after failure of first and second line therapy, as defined by clinical deterioration after 72 hours of antibiotic therapy or lack of improvement after completion of antibiotic therapy; or
- 4) Acute sinusitis after failure of first line therapy, as defined by clinical deterioration after 72 h of antibiotic therapy or lack of improvement after completion of antibiotic therapy, in patients with beta-lactam (penicillin and cephalosporin) allergy; or
- 5) For use in other current Health Canada approved indications when prescribed by a specialist in Infectious Diseases."

All requests for Moxifloxacin HCl must be completed using the Select Quinolones Special Authorization Request Form (ABC 60042).

400 MG (BASE) ORAL TABLET				
00002404923	APO-MOXIFLOXACIN	APX	\$	1.5230
00002432242	AURO-MOXIFLOXACIN	AUR	\$	1.5230
00002443929	JAMP-MOXIFLOXACIN	JPC	\$	1.5230
00002447061	JAMP-MOXIFLOXACIN	JPC	\$	1.5230
00002447053	MAR-MOXIFLOXACIN	MAR	\$	1.5230
00002457814	MED-MOXIFLOXACIN	GMP	\$	1.5230
00002383381	SANDOZ MOXIFLOXACIN	SDZ	\$	1.5230
00002375702	TEVA-MOXIFLOXACIN	TEV	\$	1.5230

SECTION 4

Rare Diseases Drug Coverage Program

RARE DISEASES DRUG COVERAGE PROGRAM

Selected drug products used in the treatment of rare diseases may be considered for coverage for individuals covered under Alberta government-sponsored drug programs. The Minister of Health makes the final decisions regarding coverage under this Program, and may list a drug product under this section when the Minister considers it in the public interest to do so.¹

RARE DISEASES DRUG COVERAGE

In order to be eligible for the Rare Diseases Drug Coverage Program, an individual must:

- have Alberta government-sponsored drug coverage;
 - be continuously registered in the Alberta Health Care Insurance Plan for a minimum of five years unless:
 - the individual is less than five years of age at the date of the application, then the individual's parent/guardian/legal representative must be registered continuously in the Alberta Health Care Insurance Plan for a minimum of five years;
- OR
- the individual has moved to Alberta from another province or territory in Canada (the "province of origin"), and immediately prior to moving to Alberta, was covered for a drug product listed in this section in the province of origin by a provincial or territorial government sponsored drug plan, and the individual has been registered in the Alberta Health Care Insurance Plan (the individual must provide supporting documentation from the province of origin to prove prior coverage).
- meet the clinical criteria for a rare disease drug product published on the *List*;
 - have a *Rare Diseases Drug Coverage Application* form ("Application") submitted on their behalf to Alberta Blue Cross by the individual's "Rare Disease Specialist";
 - have the Application reviewed and approved for coverage by the Alberta Rare Diseases Clinical Review Panel ("Review Panel")
 - complete the required forms, and consent to and acknowledge that
 - approval for initial and continued coverage is conditional upon clinical outcomes;
 - regular monitoring of the individual's clinical outcomes will be required, and
 - that coverage will be discontinued if there is inadequate response or the individual's condition deteriorates as outlined in the withdrawal criteria established in relation to a specific rare diseases drug product and/or as assessed by the Review Panel.

Contraindications

In addition to meeting the above criteria, the individual must not have the following contraindications:

- Significant illness, not including one of the rare diseases, likely to substantially alter or reduce life expectancy.

¹ Section 1 of the ADBL does not apply to the Rare Diseases Drug Coverage Program

Rare Diseases Drugs Eligible for Coverage

Drug products approved by Health Canada for the treatment of Rare Diseases may be considered for coverage in accordance with this section.

Rare Diseases are genetic, lysosomal storage disorders occurring at a rate of less than one per 50,000 for the Canadian population for a specific disease (as determined by Alberta Health).

As of April 1, 2009, drug products for the treatment of the following rare diseases are currently under consideration for coverage:

- Gaucher's disease
- Fabry disease
- MPS-I (Hurler/Hurler Scheie)
- Hunter disease
- Pompe disease

Alberta Rare Diseases Clinical Review Panel

The Alberta Rare Diseases Clinical Review Panel ("Review Panel") is a review panel composed of specialists treating rare diseases and other health professionals with clinical expertise, appointed by the Minister of Health.

The Review Panel's functions include:

- Providing advice to Alberta Health regarding the Rare Diseases Drug Coverage Program;
- Reviewing and applying clinical knowledge and skills to individual applications for Rare Diseases Drug Coverage; and
- Providing advice to the Expert Committee on Drug Evaluation and Therapeutics regarding drug products under consideration for coverage under this section, clinical criteria for rare diseases drug products and identifying appropriate "Rare Disease Specialists".

Process for Rare Diseases Drug Coverage

Participating "Rare Disease Specialists" must complete a Rare Diseases Drug Coverage Application form for each individual. The form must be the one specific to the rare diseases drug product being requested. The completed application may be forwarded to Alberta Blue Cross by mail or by facsimile.

To be considered for Rare Diseases Drug Coverage, the "Rare Disease Specialist" must confirm the individual (or individual's parent/guardian/legal representative) has been provided with information regarding the Rare Diseases Drug Coverage Program and have completed the required forms.

Alberta Blue Cross, in providing administrative support to the Review Panel, receives and screens each application for completeness, then forwards to Alberta Health to confirm that the individual has met the Alberta Health Care Insurance Plan registration requirement (please see above).

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

**ALBERTA HUMAN SERVICES DRUG BENEFIT SUPPLEMENT
RARE DISEASES DRUG COVERAGE PROGRAM**

Once it has been confirmed that the individual meets the Alberta Health Care Insurance Plan registration requirement, Alberta Blue Cross forwards the application to the Review Panel for assessment. Alberta Blue Cross responds to applicants on the Review Panel's behalf. After an application has been assessed by the Review Panel, Alberta Blue Cross notifies the individual's "Rare Disease Specialist" and the individual or individual's parent/guardian/legal representative by letter of the Review Panel's decision. Eligibility will be effective the date coverage is approved by the Review Panel.

Renewals require a new drug product specific Rare Diseases Drug Coverage Application form that is completed by a "Rare Disease Specialist".

To be eligible for Rare Diseases Drug Coverage, prescriptions must be written by a "Rare Disease Specialist" as identified by the eligibility criteria for the drug product. To avoid wastage, prescription quantities are limited to a one-month supply. Extended quantity and vacation supplies are not permitted. Out-of-country claims will only be reimbursed in accordance with standard rules and regulations; individuals should verify with Alberta Blue Cross these rules and regulations prior to obtaining drug products out of the country

Government will not be responsible for reimbursement of costs associated with wastage or improper storage of rare diseases drug products.

Prior approval must be granted to ensure coverage. Approval is granted for a specific period, to a maximum of 12 months. If continued treatment is necessary, it is the responsibility of the individual or individual's parent/guardian/legal representative and the "Rare Disease Specialist" to re-apply for drug product coverage prior to the expiry date of the authorization period.

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

PART 2

Pharmacologic – Therapeutic Classification of Drugs

00:00 NON-CLASSIFIED DRUGS

00:00.02

(DIABETES SUPPLIES)**BLOOD GLUCOSE METER**

00000990024	BLOOD GLUCOSE METER	XXX	\$	0.0000
-------------	---------------------	-----	----	--------

The blood glucose meter is a benefit upon written order from a physician, and is limited to a "one time" benefit not exceeding \$70.00 per participant.

DIABETES SUPPLIES

<input checked="" type="checkbox"/>	00000999955	BLOOD GLUCOSE TEST STRIPS	XXX	\$	0.0000
<input checked="" type="checkbox"/>	00000999941	BLOOD LETTING LANCET	XXX	\$	0.0000
<input checked="" type="checkbox"/>	00000990058	GLUCOSE CALIBRATION SOLUTION	XXX	\$	0.0000
<input checked="" type="checkbox"/>	00000990045	INFUSION SETS (TUBING & NEEDLE)	XXX	\$	0.0000
<input checked="" type="checkbox"/>	00000990057	INSULIN CARTRIDGES / RESERVOIRS	XXX	\$	0.0000
<input checked="" type="checkbox"/>	00000999985	INSULIN PEN NEEDLES	XXX	\$	0.0000
<input checked="" type="checkbox"/>	00000999952	INSULIN SYRINGES	XXX	\$	0.0000
<input checked="" type="checkbox"/>	00000999942	LANCING DEVICE	XXX	\$	0.0000
<input checked="" type="checkbox"/>	00000999957	URINE TEST STRIPS	XXX	\$	0.0000

02:00 PEDIATRIC COUGH AND COLD PREPARATIONS

02:00

BROMPHENIRAMINE MALEATE/ PHENYLEPHRINE HCL

RESTRICTED BENEFIT - This product is a benefit for patients 6 to 17 years of age inclusive.

0.4 MG / ML * 1 MG / ML ORAL LIQUID

00002243980	DIMETAPP COLD	PDH	\$	0.0513
-------------	---------------	-----	----	--------

DEXTROMETHORPHAN HBR/ PSEUDOEPHEDRINE HCL

RESTRICTED BENEFIT - This product is a benefit for patients 6 to 17 years of age inclusive.

1.5 MG / ML * 3 MG / ML ORAL LIQUID

00002044013	ROBITUSSIN CHILDRENS COUGH AND COLD	PDH	\$	0.0508
-------------	-------------------------------------	-----	----	--------

04:00 ANTIHISTAMINE DRUGS

04:02

PEDIATRIC ANTIHISTAMINES**CYPROHEPTADINE HCL**

RESTRICTED BENEFIT - This product is a benefit for patients up to 17 years of age inclusive.

4 MG ORAL TABLET

<input checked="" type="checkbox"/>	00002332248	CYPROHEPTADINE	JPC	\$	0.2310
<input checked="" type="checkbox"/>	00002245667	EURO-CYPROHEPTADINE	SDZ	\$	0.2483

DESLORATADINE

RESTRICTED BENEFIT - This product is a benefit for patients up to 17 years of age inclusive.

0.5 MG / ML ORAL SYRUP

00002247193	AERIUS KIDS	BIC	\$	0.0700
-------------	-------------	-----	----	--------

04:00 ANTIHISTAMINE DRUGS**04:02 PEDIATRIC ANTIHISTAMINES****DIPHENHYDRAMINE HCL**

RESTRICTED BENEFIT - This product is a benefit for patients up to 17 years of age inclusive.

2.5 MG / ML ORAL ELIXIR

00002298503	DIPHENHYDRAMINE	JPC	\$	0.0303
-------------	-----------------	-----	----	--------

LORATADINE

RESTRICTED BENEFIT - This product is a benefit for patients up to 17 years of age inclusive.

1 MG / ML ORAL SYRUP

00002241523	CLARITIN	BIC	\$	0.0542
-------------	----------	-----	----	--------

08:00 ANTI-INFECTIVE AGENTS**08:14.08 ANTIFUNGALS
(AZOLES)****FLUCONAZOLE****150 MG ORAL CAPSULE**

<input checked="" type="checkbox"/>	00002241895	APO-FLUCONAZOLE-150	APX	\$	3.9400
<input checked="" type="checkbox"/>	00002432471	JAMP-FLUCONAZOLE	JPC	\$	3.9400
<input checked="" type="checkbox"/>	00002428792	MAR-FLUCONAZOLE-150	MAR	\$	3.9400

12:00 AUTONOMIC DRUGS**12:92 MISCELLANEOUS AUTONOMIC DRUGS****BUPROPION HCL****150 MG ORAL SUSTAINED-RELEASE TABLET**

<input checked="" type="checkbox"/>	00002238441	ZYBAN	VCL	\$	1.0476
-------------------------------------	-------------	-------	-----	----	--------

NICOTINE

RESTRICTED BENEFIT - Coverage is limited to a lifetime maximum of \$500.00 per participant for all over the counter smoking cessation products listed in the Alberta Human Services Drug Benefit Supplement.

1 MG / DOSE BUCCAL SPRAY

00080038858	NICORETTE QUICKMIST	MCL	\$	0.2119
-------------	---------------------	-----	----	--------

2 MG ORAL GUM

00002091933	NICORETTE	JJI	\$	0.3027
-------------	-----------	-----	----	--------

4 MG ORAL GUM

00002091941	NICORETTE	JJI	\$	0.3027
-------------	-----------	-----	----	--------

10 MG INHALATION CARTRIDGE

00002241742	NICORETTE INHALER	JJI	\$	0.7567
-------------	-------------------	-----	----	--------

7 MG/DAY TRANSDERMAL PATCH

<input checked="" type="checkbox"/>	00001943057	HABITROL 7 MG/DAY	GKC	\$	2.6786
<input checked="" type="checkbox"/>	00002241227	TRANSDERMAL NICOTINE 7 MG/DAY	GKC	\$	2.7257
<input checked="" type="checkbox"/>	00002093111	NICODERM 7 MG/DAY	JJI	\$	3.6157

14 MG/DAY TRANSDERMAL PATCH

<input checked="" type="checkbox"/>	00001943065	HABITROL 14 MG/DAY	GKC	\$	2.6786
<input checked="" type="checkbox"/>	00002241226	TRANSDERMAL NICOTINE 14 MG/DAY	GKC	\$	2.7257
<input checked="" type="checkbox"/>	00002093138	NICODERM 14 MG/DAY	JJI	\$	3.6157

21 MG/DAY TRANSDERMAL PATCH

<input checked="" type="checkbox"/>	00001943073	HABITROL 21 MG/DAY	GKC	\$	2.6786
<input checked="" type="checkbox"/>	00002241228	TRANSDERMAL NICOTINE 21 MG/DAY	GKC	\$	2.7257
<input checked="" type="checkbox"/>	00002093146	NICODERM 21 MG/DAY	JJI	\$	3.6157

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

20:00 BLOOD FORMULATION, COAGULATION AND THROMBOSIS**20:04.04 ANTIANEMIA DRUGS
(IRON PREPARATIONS)****FERROUS FUMARATE**

RESTRICTED BENEFIT - This product is a benefit for patients up to 17 years of age inclusive.

60 MG / ML ORAL SUSPENSION

<input checked="" type="checkbox"/>	00080029822	JAMP-FERROUS FUMARATE	JPC	\$	0.0821
<input checked="" type="checkbox"/>	00001923439	PALAFER	VCL	\$	0.0900

FERROUS SULFATE

RESTRICTED BENEFIT - This product is a benefit for patients up to 17 years of age inclusive.

30 MG / ML ORAL LIQUID

	00080008295	JAMP FERROUS SULFATE	JPC	\$	0.0272
--	-------------	----------------------	-----	----	--------

30 MG / ML ORAL SYRUP

	00000758469	FERODAN	ODN	\$	0.0272
	00000017884	FER-IN-SOL	MJO	\$	0.0519

75 MG / ML ORAL DROPS

	00002237385	FERODAN INFANT	ODN	\$	0.1432
<input checked="" type="checkbox"/>	00080008309	JAMP FERROUS SULFATE INFANT DROPS	JPC	\$	0.1432
	00000762954	FER-IN-SOL	MJO	\$	0.2558

28:00 CENTRAL NERVOUS SYSTEM AGENTS**28:08.04.92 ANALGESICS AND ANTIPYRETICS
NONSTEROIDAL ANTI-INFLAMMATORY AGENTS
(OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTS)****IBUPROFEN**

RESTRICTED BENEFIT - This product is a benefit for patients up to 17 years of age inclusive.

20 MG / ML ORAL SUSPENSION

<input checked="" type="checkbox"/>	00002242365	CHILDREN'S MOTRIN	MCL	\$	0.0458
<input checked="" type="checkbox"/>	00002232297	CHILDREN'S ADVIL	PDH	\$	0.0639

28:00 CENTRAL NERVOUS SYSTEM AGENTS**28:08.92 ANALGESICS AND ANTIPYRETICS
(MISCELLANEOUS ANALGESICS AND ANTIPYRETICS)****ACETAMINOPHEN****500 MG ORAL TABLET**

<input checked="" type="checkbox"/>	00002355299	JAMP-ACETAMINOPHEN BLAZON	JPC	\$	0.0271
<input checked="" type="checkbox"/>	00001939122	JAMP-ACETAMINOPHEN EXTRA STRENGTH	JPC	\$	0.0271
<input checked="" type="checkbox"/>	00002252813	ACETAMINOPHEN EXTRA STRENGTH	CEL	\$	0.0285
	00000545007	APO-ACETAMINOPHEN	APX	\$	0.0285
	00002229977	APO-ACETAMINOPHEN (CAPLET)	APX	\$	0.0285
	00000482323	NOVO GESIC FORTE	TEV	\$	0.0285
	00000559407	TYLENOL EXTRA STRENGTH	MCL	\$	0.1165
	00000723908	TYLENOL EXTRA-STRENGTH (CAPLET)	MCL	\$	0.1165

32 MG / ML ORAL SOLUTION

	00002027798	PEDIATRIX	TEV	\$	0.0434
--	-------------	-----------	-----	----	--------

16 MG / ML ORAL SYRUP

	00000884553	CHILDRENS TEMPRA	PAL	\$	0.0407
--	-------------	------------------	-----	----	--------

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:08.92 ANALGESICS AND ANTIPYRETICS
(MISCELLANEOUS ANALGESICS AND ANTIPYRETICS)

ACETAMINOPHEN**32 MG / ML ORAL SYRUP**

00000875996	TEMPRA D.S.	PAL	\$	0.0407
-------------	-------------	-----	----	--------

80 MG / ML ORAL DROPS

00002027801	PEDIATRIX	TEV	\$	0.1510
-------------	-----------	-----	----	--------

120 MG RECTAL SUPPOSITORY

00002230434	ACET 120	PPH	\$	0.9315
-------------	----------	-----	----	--------

325 MG RECTAL SUPPOSITORY

00002230436	ACET 325	PPH	\$	0.9315
-------------	----------	-----	----	--------

650 MG RECTAL SUPPOSITORY

00002230437	ACET 650	PPH	\$	0.9315
-------------	----------	-----	----	--------

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:16.08.04 PSYCHOTHERAPEUTIC AGENTS
ANTIPSYCHOTICS
(ATYPICAL ANTIPSYCHOTICS)

ARIPIPRAZOLE**2 MG ORAL TABLET**

00002471086	APO-ARIPIPRAZOLE	APX	\$	0.8092
-------------	------------------	-----	----	--------

00002460025	AURO-ARIPIPRAZOLE	AUR	\$	0.8092
-------------	-------------------	-----	----	--------

00002466635	PMS-ARIPIPRAZOLE	PMS	\$	0.8092
-------------	------------------	-----	----	--------

00002473658	SANDOZ ARIPIPRAZOLE	SDZ	\$	0.8092
-------------	---------------------	-----	----	--------

00002464144	TEVA-ARIPIPRAZOLE	TEV	\$	0.8092
-------------	-------------------	-----	----	--------

00002322374	ABILIFY	OTS	\$	3.1618
-------------	---------	-----	----	--------

ALBERTA HUMAN SERVICES RESTRICTED BENEFIT

This Drug Product is a benefit for Alberta Human Services clients 13 years of age and older.

5 MG ORAL TABLET

00002471094	APO-ARIPIPRAZOLE	APX	\$	0.9046
-------------	------------------	-----	----	--------

00002460033	AURO-ARIPIPRAZOLE	AUR	\$	0.9046
-------------	-------------------	-----	----	--------

00002466643	PMS-ARIPIPRAZOLE	PMS	\$	0.9046
-------------	------------------	-----	----	--------

00002473666	SANDOZ ARIPIPRAZOLE	SDZ	\$	0.9046
-------------	---------------------	-----	----	--------

00002322382	ABILIFY	OTS	\$	3.5591
-------------	---------	-----	----	--------

ALBERTA HUMAN SERVICES RESTRICTED BENEFIT

This Drug Product is a benefit for Alberta Human Services clients 13 years of age and older.

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:16.08.04 PSYCHOTHERAPEUTIC AGENTS
 ANTIPSYCHOTICS
 (ATYPICAL ANTIPSYCHOTICS)

ARIPIPIRAZOLE**10 MG ORAL TABLET**

00002471108	APO-ARIPIPIRAZOLE	APX	\$	1.0754
00002460041	AURO-ARIPIPIRAZOLE	AUR	\$	1.0754
00002466651	PMS-ARIPIPIRAZOLE	PMS	\$	1.0754
00002473674	SANDOZ ARIPIPIRAZOLE	SDZ	\$	1.0754
00002464160	TEVA-ARIPIPIRAZOLE	TEV	\$	1.0754
00002322390	ABILIFY	OTS	\$	4.1016

RESTRICTED BENEFIT - This product is a benefit for Alberta Human Services clients 13 years of age and older.

15 MG ORAL TABLET

00002471116	APO-ARIPIPIRAZOLE	APX	\$	1.2692
00002460068	AURO-ARIPIPIRAZOLE	AUR	\$	1.2692
00002466678	PMS-ARIPIPIRAZOLE	PMS	\$	1.2692
00002473682	SANDOZ ARIPIPIRAZOLE	SDZ	\$	1.2692
00002464179	TEVA-ARIPIPIRAZOLE	TEV	\$	1.2692
00002322404	ABILIFY	OTS	\$	4.1016

RESTRICTED BENEFIT - This product is a benefit for Alberta Human Services clients 13 years of age and older.

20 MG ORAL TABLET

00002471124	APO-ARIPIPIRAZOLE	APX	\$	1.0017
00002460076	AURO-ARIPIPIRAZOLE	AUR	\$	1.0017
00002466686	PMS-ARIPIPIRAZOLE	PMS	\$	1.0017
00002473690	SANDOZ ARIPIPIRAZOLE	SDZ	\$	1.0017
00002464187	TEVA-ARIPIPIRAZOLE	TEV	\$	1.0017
00002322412	ABILIFY	OTS	\$	4.1016

RESTRICTED BENEFIT - This product is a benefit for Alberta Human Services clients 13 years of age and older.

30 MG ORAL TABLET

00002471132	APO-ARIPIPIRAZOLE	APX	\$	1.0017
00002460084	AURO-ARIPIPIRAZOLE	AUR	\$	1.0017
00002466694	PMS-ARIPIPIRAZOLE	PMS	\$	1.0017
00002473704	SANDOZ ARIPIPIRAZOLE	SDZ	\$	1.0017
00002464195	TEVA-ARIPIPIRAZOLE	TEV	\$	1.0017
00002322455	ABILIFY	OTS	\$	4.1016

RESTRICTED BENEFIT - This product is a benefit for Alberta Human Services clients 13 years of age and older.

40:00 ELECTROLYTIC, CALORIC, AND WATER BALANCE**40:12 REPLACEMENT PREPARATIONS****SODIUM CHLORIDE/ POTASSIUM CHLORIDE (K+)(CL-)/ SODIUM CITRATE,ACID/ DEXTROSE**

470 MG / G * 300 MG / G * 530 MG / G * 3.56 G / G ORAL POWDER

00001931563 GASTROLYTE SAV \$ 0.1622

SODIUM CHLORIDE/ SODIUM CITRATE,ACID/ DEXTROSE/ POTASSIUM CITRATE (K+)

470 MG * 530 MG * 3.56 G * 390 MG ORAL POWDER PACKET

00080027403 JAMP REHYDRALYTE JPC \$ 0.7010

SODIUM/ POTASSIUM/ CHLORIDE/ CITRATE/ DEXTROSE

0.045 MEQ / ML * 0.02 MEQ / ML * 0.035 MEQ / ML * 0.03 MEQ / ML * 0.025 G / ML ORAL LIQUID

00002219883 PEDIATRIC ELECTROLYTE PPH \$ 0.0074

SODIUM/ POTASSIUM/ CHLORIDE/ CITRATE/ ZINC/ DEXTROSE

0.045 MEQ / ML * 0.02 MEQ / ML * 0.035 MEQ / ML * 0.014 MEQ / ML * 0.0078 MG / ML * 0.025 G / ML ORAL SOLUTION

00080072902 PEDIALYTE (UNFLAVOURED) ABN \$ 0.0074

0.045 MEQ / ML * 0.02 MEQ / ML * 0.035 MEQ / ML * 0.0255 MEQ / ML * 0.0078 MG / ML * 0.025 G / ML ORAL SOLUTION

00080074173 PEDIALYTE (FLAVOURED) ABN \$ 0.0074

40:00 ELECTROLYTIC, CALORIC, AND WATER BALANCE**40:20 CALORIC AGENTS****INFANT FORMULA****ORAL LIQUID**

00000999449 ALIMENTUM ABN \$ 0.0066

ORAL POWDER

<input checked="" type="checkbox"/>	00000999788	SIMILAC ALIMENTUM	ABN	\$	0.0381
<input checked="" type="checkbox"/>	00000999465	SIMILAC NEOSURE	ABN	\$	0.0403
<input checked="" type="checkbox"/>	00000999564	ENFAMIL ENFACARE A+	MJO	\$	0.0453
<input checked="" type="checkbox"/>	00000999520	NUTRAMIGEN A+ HYPOALLERGENIC	MJO	\$	0.0457

NUTRITIONAL PRODUCT**ORAL LIQUID**

<input checked="" type="checkbox"/>	00000999889	ISOSOURCE 1.2	NHN	\$	0.0062
<input checked="" type="checkbox"/>	00000999895	ISOSOURCE FIBRE 1.2	NHN	\$	0.0074
<input checked="" type="checkbox"/>	00000999888	ISOSOURCE 1.5	NHN	\$	0.0075
<input checked="" type="checkbox"/>	00000999896	ISOSOURCE FIBRE 1.5	NHN	\$	0.0075
<input checked="" type="checkbox"/>	00009998877	ISOSOURCE 2.0	NHN	\$	0.0108
<input checked="" type="checkbox"/>	00000999938	JEVITY 1 CAL	ABN	\$	0.0115

NUTRITIONAL PRODUCT (ADULT MEAL REPLACEMENT)**ORAL LIQUID**

<input checked="" type="checkbox"/>	00000999932	BOOST 1.5 PLUS CALORIES	NHN	\$	0.0066
<input checked="" type="checkbox"/>	00000999920	BOOST	NHN	\$	0.0072
<input checked="" type="checkbox"/>	00000999921	BOOST PLUS CALORIES	NHN	\$	0.0072
<input checked="" type="checkbox"/>	00000999902	ENSURE PLUS	ABN	\$	0.0080
<input checked="" type="checkbox"/>	00000999901	ENSURE REGULAR	ABN	\$	0.0080
<input checked="" type="checkbox"/>	00000999525	ENSURE SCFOS FIBRE	ABN	\$	0.0080
<input checked="" type="checkbox"/>	00000999409	RESOURCE 2.0	NHN	\$	0.0086

40:00 ELECTROLYTIC, CALORIC, AND WATER BALANCE**40:20 CALORIC AGENTS****NUTRITIONAL PRODUCT (ADULT)****ORAL LIQUID**

<input checked="" type="checkbox"/>	00000999966	COMPLEAT	NHN	\$	0.0081
<input checked="" type="checkbox"/>	00000989996	VITAL PEPTIDE 1 CAL	ABN	\$	0.0119
<input checked="" type="checkbox"/>	00000989997	VITAL PEPTIDE 1.5 CAL	ABN	\$	0.0119

NUTRITIONAL PRODUCT (DIABETIC)**ORAL LIQUID**

<input checked="" type="checkbox"/>	00000999413	RESOURCE DIABETIC	NHN	\$	0.0070
<input checked="" type="checkbox"/>	00000999940	GLUCERNA	ABN	\$	0.0079

ORAL LIQUID

	00000999483	BOOST DIABETIC	NHN	\$	0.0072
--	-------------	----------------	-----	----	--------

Not eligible for coverage for AISH (Group 19823 Section X) clients.

NUTRITIONAL PRODUCT (PEDIATRIC)**ORAL LIQUID**

<input checked="" type="checkbox"/>	00000999418	NUTREN JUNIOR	NHN	\$	0.0067
<input checked="" type="checkbox"/>	00000999419	NUTREN JUNIOR FIBRE W PREBIO 1	NHN	\$	0.0067
<input checked="" type="checkbox"/>	00000999458	RESOURCE KID ESSENTIALS 1.5 CAL	NHN	\$	0.0097
<input checked="" type="checkbox"/>	00000999933	PEDIASURE	ABN	\$	0.0108
<input checked="" type="checkbox"/>	00000990029	PEDIASURE FIBRE	ABN	\$	0.0108
<input checked="" type="checkbox"/>	00000989998	PEDIASURE PEPTIDE 1 CAL	ABN	\$	0.0110

NUTRITIONAL PRODUCT (RENAL)**ORAL LIQUID**

<input checked="" type="checkbox"/>	00000990056	NOVASOURCE RENAL	NHN	\$	0.0089
<input checked="" type="checkbox"/>	00000999545	NEPRO	ABN	\$	0.0095
<input checked="" type="checkbox"/>	00000999414	SUPLENA	ABN	\$	0.0100

52:00 EYE, EAR, NOSE, AND THROAT (EENT) PREPARATIONS**52:02 ANTIALLERGIC AGENTS****SODIUM CROMOGLYCATE**

Not a benefit for Alberta Human Services Group 19824 and Group 20403 clients.

2% OPHTHALMIC SOLUTION

	00002009277	CROMOLYN	PPH	\$	0.9975
	00002230621	OPTICROM	ALL	\$	1.0130

52:00 EYE, EAR, NOSE, AND THROAT (EENT) PREPARATIONS**52:92 MISCELLANEOUS EENT DRUGS****SODIUM CHLORIDE****0.9% NASAL SOLUTION**

	00080024901	SALINEX	EXP	\$	0.1650
--	-------------	---------	-----	----	--------

56:00 GASTROINTESTINAL DRUGS**56:08 ANTIDIARRHEA AGENTS****LOPERAMIDE HCL**

2 MG ORAL TABLET

00002228351 PMS-LOPERAMIDE (CAPLET) PMS \$ 0.0952

00002132591 TEVA-LOPERAMIDE (CAPLET) TEV \$ 0.0952

0.13 MG / ML ORAL SOLUTION

00002291800 IMODIUM MCL \$ 0.0354

56:00 GASTROINTESTINAL DRUGS**56:12 CATHARTICS AND LAXATIVES****BISACODYL**

5 MG ORAL ENTERIC-COATED TABLET

00000254142 DULCOLAX SAV \$ 0.1950

10 MG RECTAL SUPPOSITORY

 00002241091 THE MAGIC BULLET DCM \$ 0.9100 00000003875 DULCOLAX SAV \$ 1.1604**DOCUSATE SODIUM**

RESTRICTED BENEFIT - This product is a benefit for patients up to 17 years of age inclusive.

4 MG / ML ORAL SYRUP

00002086018 COLACE WSB \$ 0.0220

00000870226 RATIO-DOCUSATE SODIUM TEV \$ 0.0220

10 MG / ML ORAL DROPS

00002090163 COLACE WSB \$ 0.1770

GLYCERIN

RESTRICTED BENEFIT - This product is a benefit for patients up to 17 years of age inclusive.

RECTAL PEDIATRIC SUPPOSITORY

00002020815 GLYCERIN INFANT TEV \$ 0.1706

**POLYETHYLENE GLYCOL/ POTASSIUM CHLORIDE (K+)/
SODIUM SULFATE/ SODIUM CHLORIDE/ SODIUM
BICARBONATE**

238.18 G / G * 3.05 G / G * 22.96 G / G * 5.85 G / G * 6.76 G / G ORAL POWDER

00000777838 PEG-LYTE PPH \$ 0.0785

RESTRICTED BENEFIT - This product is a benefit for patients 18 years of age and older for bowel cleansing prior to procedures (such as colonoscopy).

Coverage is restricted to a total of 840g (i.e. 3 fills of 280g) per patient per year.

**POLYETHYLENE GLYCOL/ SODIUM SULFATE/ SODIUM
BICARBONATE/ SODIUM CHLORIDE/ POTASSIUM CHLORIDE
(K+)**

238.8 G / G * 22.7 G / G * 6.7 G / G * 5.8 G / G * 3 G / G ORAL POWDER

00000677442 COLYTE PPH \$ 0.0785

RESTRICTED BENEFIT - This product is a benefit for patients 18 years of age and older for bowel cleansing prior to procedures (such as colonoscopy).

Coverage is restricted to a total of 840g (i.e. 3 fills of 280g) per patient per year.

56:00 GASTROINTESTINAL DRUGS**56:12 CATHARTICS AND LAXATIVES****SODIUM PHOSPHATE/ SODIUM ACID PHOSPHATE****10.4 G / ENM * 3.9 G / ENM RECTAL ENEMA**

00002231170 ENE-MED HJS \$ 1.9500

00000009911 FLEET ENEMA CBF \$ 3.8800

10.4 G / ENM * 3.9 G / ENM RECTAL PEDIATRIC ENEMA

00000108065 FLEET ENEMA PEDIATRIC (65 ML) CBF \$ 3.9000

RESTRICTED BENEFIT - This product is a benefit for patients up to 17 years of age inclusive.

56:00 GASTROINTESTINAL DRUGS**56:16 DIGESTANTS****LACTASE****3,000 UNIT ORAL TABLET**

00002230653 LACTAID MCL \$ 0.1407

4,500 UNIT ORAL TABLET

00002230654 EXTRA STRENGTH LACTAID MCL \$ 0.2119

9,000 UNIT ORAL TABLET 00080070358 JAMP-LACTASE ENZYME JPC \$ 0.2928 00002231507 LACTAID ULTRA (CAPLET) MCL \$ 0.3517**3,000 UNIT ORAL CHEWABLE TABLET**

00002239139 JAMP-LACTASE ENZYME JPC \$ 0.1036

4,500 UNIT ORAL CHEWABLE TABLET

00080018706 JAMP-LACTASE ENZYME JPC \$ 0.1283

56:00 GASTROINTESTINAL DRUGS**56:22.08 ANTIEMETICS
(ANTI-HISTAMINES)****DIMENHYDRINATE****50 MG ORAL TABLET**

00002245416 JAMP-DIMENHYDRINATE JPC \$ 0.0225

50 MG RECTAL SUPPOSITORY

00000392553 SANDOZ DIMENHYDRINATE SDZ \$ 0.6080

100 MG RECTAL SUPPOSITORY

00000392545 SANDOZ DIMENHYDRINATE SDZ \$ 0.6195

84:00 SKIN AND MUCOUS MEMBRANE AGENTS**84:04.08.08 ANTI-INFECTIVES
ANTIFUNGALS
(AZOLES)****CLOTRIMAZOLE****1% TOPICAL CREAM**

00002239432 CANESTEN EXTERNAL CREAM REFILL BIC \$ 0.3962

1% VAGINAL CREAM 00000812366 CLOTRIMADERM TAR \$ 0.2147 00002150891 CANESTEN 6 BIC \$ 0.2560**2% VAGINAL CREAM** 00000812374 CLOTRIMADERM TAR \$ 0.4296 00002150905 CANESTEN 3 BIC \$ 0.5120

84:00 SKIN AND MUCOUS MEMBRANE AGENTS

84:04.08.08 ANTI-INFECTIVES
ANTIFUNGALS
(AZOLES)

CLOTRIMAZOLE

10 % VAGINAL CREAM

00002150883	CANESTEN 1	BIC	\$	2.5599
-------------	------------	-----	----	--------

CLOTRIMAZOLE/ CLOTRIMAZOLE

1 % * 10 % TOPICAL/VAGINAL CREAM/CREAM

00002230509	CANESTEN 1 CREAM COMBI-PAK	BIC	\$	13.9755
-------------	----------------------------	-----	----	---------

200 MG * 1 % VAGINAL/TOPICAL TABLET/CREAM

00002264099	CANESTEN 3 COMFORTAB COMBI-PAK	BIC	\$	13.9755
-------------	--------------------------------	-----	----	---------

500 MG * 1 % VAGINAL/TOPICAL TABLET/CREAM

00002264102	CANESTEN 1 COMFORTAB COMBI-PAK	BIC	\$	13.9755
-------------	--------------------------------	-----	----	---------

MICONAZOLE NITRATE

2 % VAGINAL CREAM

00002231106	MICOZOLE	TAR	\$	0.2721
-------------	----------	-----	----	--------

84:00 SKIN AND MUCOUS MEMBRANE AGENTS

84:04.08.28 ANTI-INFECTIVES
ANTIFUNGALS
(POLYENES)

NYSTATIN

RESTRICTED BENEFIT - This product is a benefit for patients up to 17 years of age inclusive.

100,000 UNIT / G TOPICAL CREAM

00000716871	NYADERM	TAR	\$	0.0665
-------------	---------	-----	----	--------

84:00 SKIN AND MUCOUS MEMBRANE AGENTS

84:04.12 ANTI-INFECTIVES
(SCABICIDES AND PEDICULICIDES)

DIMETHICONE

50 % TOPICAL SOLUTION

00002373785	NYDA	GXP	\$	0.4484
-------------	------	-----	----	--------

ISOPROPYL MYRISTATE

50 % TOPICAL SOLUTION

00002279592	RESULTZ	ARA	\$	0.1058
-------------	---------	-----	----	--------

PERMETHRIN

5 % TOPICAL CREAM

00002219905	NIX DERMAL	GKC	\$	0.4977
-------------	------------	-----	----	--------

5 % TOPICAL LOTION

00002231348	KWELLADA-P	MTC	\$	0.5053
-------------	------------	-----	----	--------

10 MG / ML TOPICAL RINSE

00000771368	NIX CREME	IPH	\$	0.1907
-------------	-----------	-----	----	--------

00002231480	KWELLADA-P CREME	MTC	\$	0.2328
-------------	------------------	-----	----	--------

84:00 SKIN AND MUCOUS MEMBRANE AGENTS

84:04.12 ANTI-INFECTIVES
(SCABICIDES AND PEDICULICIDES)

PYRETHRINS/ PIPERONYL BUTOXIDE

0.33 % * 3 % TOPICAL SHAMPOO

00002125447	R & C SHAMPOO WITH CONDITIONER	MTC	\$	0.1558
-------------	--------------------------------	-----	----	--------

88:00 VITAMINS

88:16 VITAMIN D

VITAMIN D3

RESTRICTED BENEFIT - This product is a benefit for patients up to 17 years of age inclusive.

400 UNIT / ML ORAL DROPS

<input checked="" type="checkbox"/>	00080003038	JAMP-VITAMIN D	JPC	\$	0.1497
<input checked="" type="checkbox"/>	00000762881	D-VI-SOL INFANT	MJO	\$	0.1996
<input checked="" type="checkbox"/>	00080019649	D3-DOL	JPC	\$	5.3892

88:00 VITAMINS

88:28 MULTIVITAMIN PREPARATIONS

**VITAMIN A ACETATE/ THIAMINE MONONITRATE/ RIBOFLAVIN
(VITAMIN B2)/ PYRIDOXINE HCL/ CYANOCOBALAMIN/ SODIUM
ASCORBATE/ VITAMIN D/ FOLIC ACID/ NIACINAMIDE
(NICOTINAMIDE)**

RESTRICTED BENEFIT - This product is a benefit for patients up to 17 years of age inclusive.

1,600 UNIT (BASE) * 1.5 MG * 1.5 MG * 1 MG * 3 MCG * 50 MG * 400 UNIT * 0.1 MG * 8 MG ORAL CHEWABLE TABLET

00002247975	FLINTSTONES MULTI VITAMINS W EXTRA C BIC		\$	0.1305
-------------	--	--	----	--------

VITAMIN A PALMITATE/ VITAMIN D/ ASCORBIC ACID

RESTRICTED BENEFIT - This product is a benefit for patients up to 17 years of age inclusive.

2,500 UNIT / ML (BASE) * 667 UNIT / ML * 50 MG / ML ORAL DROPS

00000762903	TRI-VI-SOL	MJO	\$	0.2346
-------------	------------	-----	----	--------

**VITAMIN A PALMITATE/ VITAMIN D/ SODIUM ASCORBATE/
THIAMINE HCL/ RIBOFLAVIN (VITAMIN B2)/ NIACINAMIDE
(NICOTINAMIDE)**

RESTRICTED BENEFIT - This product is a benefit for patients up to 17 years of age inclusive.

1,500 UNIT / ML * 400 UNIT / ML * 30 MG / ML * 0.5 MG / ML * 0.6 MG / ML * 4 MG / ML ORAL DROPS

00000762946	POLY-VI-SOL	MJO	\$	0.2346
-------------	-------------	-----	----	--------

88:00 VITAMINS

88:28.01 MULTIVITAMIN PREPARATIONS
(VITAMINS & MINERALS)

**BETA CAROTENE/ BIOTIN/ CALCIUM CARBONATE/ CHROMIUM
CHLORIDE/ COPPER CITRATE/ FOLIC ACID/ POTASSIUM
IODIDE/ IRON/ MAGNESIUM OXIDE/ MANGANESE/ SODIUM
MOLYBDATE/ NIACINAMIDE (NICOTINAMIDE)/ CALCIUM D-
PANTOTHENATE/ RIBOFLAVIN (VITAMIN B2)/ SODIUM
SELENATE/ THIAMINE MONONITRATE/ VITAMIN A ACETATE/
CYANOCOBALAMIN/ PYRIDOXINE HCL/ ASCORBIC ACID/
VITAMIN D/ VITAMIN E (DL-ALPHA TOCOPHERYL ACETATE)/
ZINC OXIDE**

5,400 MCG * 24 MCG * 250 MG * 9 MCG * 0.3 MG * 600 MCG * 225 MCG * 24 MG * 50 MG * 1.2 MG * 28 MCG * 8
MG * 3.6 MG * 0.9 MG * 17 MCG * 0.9 MG * 462 MCG * 2.8 MCG * 1.4 MG * 70 MG * 15 MCG * 4.8 MG * 2.4 MG
ORAL TABLET

00080082297 NESTLE MATERNA NES \$ 0.1456

**VITAMIN A ACETATE/ THIAMINE MONONITRATE/ RIBOFLAVIN
(VITAMIN B2)/ PYRIDOXINE HCL/ CYANOCOBALAMIN/ SODIUM
ASCORBATE/ VITAMIN D/ FOLIC ACID/ NIACINAMIDE
(NICOTINAMIDE)/ FERROUS FUMARATE**

RESTRICTED BENEFIT - This product is a benefit for patients up to 17 years of age
inclusive.

1,600 UNIT (BASE) * 1.5 MG * 1.5 MG * 1 MG * 3 MCG * 50 MG * 400 UNIT * 0.1 MG * 8 MG * 4 MG (BASE)
ORAL CHEWABLE TABLET

00002247995 FLINTSTONES MULTI VITAMINS PLUS IRON BIC \$ 0.1305

92:00 MISCELLANEOUS THERAPEUTIC AGENTS

92:00

INSTANT FOOD THICKENER**ORAL POWDER**

<input checked="" type="checkbox"/>	00000999455	CONSIST-RITE	DFI	\$	0.0179
<input checked="" type="checkbox"/>	00000999453	RESOURCE THICKENUP	NHN	\$	0.0223
<input checked="" type="checkbox"/>	00000999561	RESOURCE THICKENUP CLEAR	NHN	\$	0.3065

APPENDICES

Pharmaceutical Manufacturers

Alphabetical List of
Pharmaceutical Products

Numerical List by Drug
Identification Number

Appendix 2 Pharmaceutical Manufacturers

A

ABN Abbott Nutrition
ACP Accel Pharma Inc.
ALL Allergan Inc.
APH Actavis Pharma Company
APX Apotex Inc.
ARA Aralez Pharmaceuticals Inc.
AUR Auro Pharma Inc.
AXC Aptalis Pharma Canada Inc.
AZC AstraZeneca Canada Inc.

B

BAI Bayer Inc.
BIC Bayer Inc. Consumer Care

C

CAM Cambrooke Therapeutics
CBF C.B. Fleet Company Inc.
CEL Cellchem Pharmaceuticals Inc.

D

DCM D & C Mobility Solutions Inc.
DFI Donmar Foods Incorporated

E

EXP Exzell Pharma

G

GKC GlaxoSmithKline Consumer Healthcare
GMP Generic Medical Partners Inc
GSK GlaxoSmithKline
GXP G Pohl Boskamp GMBH & Co/Pediapharm

H

HJS H.J. Sutton/Quality Home Products

I

IPH Insight Pharmaceuticals LLC

J

JJI Johnson & Johnson Inc.
JPC Jamp Pharma Corporation

M

MAR Marcan Pharmaceuticals Inc
MCL McNeil Consumer Healthcare
MFC Merck Canada Inc.
MFI Medical Futures Inc
MJO Mead Johnson Nutrition (Canada) Co.
MPI Mint Pharmaceuticals Inc.
MTC MedTech Products Inc.
MYP Mylan Pharmaceuticals ULC

N

NES Nestle Canada Inc.
NHN Nestle Health Science
NTP Natco Pharma (Canada) Inc.
NUN Nutricia North America

O

ODN Odan Laboratories Ltd.
OTS Otsuka Pharmaceutical Co. Ltd.

P

PAL Paladin Labs Inc.
PDH Pfizer Consumer Healthcare
PMS Pharmascience Inc.
PPH Pendopharm Inc.

R

RAN Ranbaxy Pharmaceuticals Canada Inc

S

SAV Sanofi-Aventis
SDZ Sandoz Canada Inc.
SEP Septa Pharmaceuticals Inc.
SIV Sivem Pharmaceuticals
SNS Sanis Health Inc.

T

TAR Taro Pharmaceuticals Inc.
TEV Teva Canada Limited

V

VCL Bausch Health

W

WSB Boyd Pharmaceuticals

X

XXX Miscellaneous Manufacturers

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

Appendix 2:

Alphabetical List of Pharmaceutical Products

Product Name	Page	Product Name	Page
A			
ABILIFY.....	4	BISACODYL.....	8
ABILIFY.....	5	BLOOD GLUCOSE METER.....	1
ACCEL-RIZATRIPTAN ODT.....	SEC 3.7	BLOOD GLUCOSE TEST STRIPS.....	1
ACET 120.....	4	BLOOD LETTING LANCET.....	1
ACET 325.....	4	BOOST.....	6
ACET 650.....	4	BOOST.....	SEC 3.5
ACETAMINOPHEN.....	3	BOOST 1.5 PLUS CALORIES.....	6
ACETAMINOPHEN.....	4	BOOST DIABETIC.....	7
ACETAMINOPHEN EXTRA STRENGTH.....	3	BOOST FRUIT FLAVOURED BEVERAGE.....	SEC 3.5
ACT CIPROFLOXACIN.....	SEC 3A.2	BOOST HIGH PROTEIN.....	SEC 3.5
ACT CIPROFLOXACIN.....	SEC 3A.3	BOOST PLUS CALORIES.....	6
ACT LEVOFLOXACIN.....	SEC 3A.4	BROMPHENIRAMINE MALEATE/ PHENYLEPHRINE HCL.....	1
ACT LEVOFLOXACIN.....	SEC 3A.5	BUPROPION HCL.....	2
ACT LEVOFLOXACIN.....	SEC 3A.6	C	
ACT RIZATRIPTAN.....	SEC 3.6	CANESTEN 1.....	10
AERIUS KIDS.....	1	CANESTEN 1 COMFORTAB COMBI-PAK.....	10
ALIMENTUM.....	6	CANESTEN 1 CREAM COMBI-PAK.....	10
ALMOTRIPTAN.....	SEC 3.4	CANESTEN 3.....	9
ALMOTRIPTAN MALATE.....	SEC 3.4	CANESTEN 3 COMFORTAB COMBI-PAK.....	10
AMERGE.....	SEC 3.4	CANESTEN 6.....	9
APO-ACETAMINOPHEN.....	3	CANESTEN EXTERNAL CREAM REFILL.....	9
APO-ACETAMINOPHEN (CAPLET).....	3	CCP-RIZATRIPTAN ODT.....	SEC 3.7
APO-ARIPIPRAZOLE.....	4	CCP-ZOLMITRIPTAN.....	SEC 3.8
APO-ARIPIPRAZOLE.....	5	CHILDREN'S ADVIL.....	3
APO-FLUCONAZOLE-150.....	2	CHILDREN'S MOTRIN.....	3
APO-LEVOFLOXACIN.....	SEC 3A.4	CHILDRENS TEMPRA.....	3
APO-LEVOFLOXACIN.....	SEC 3A.5	CIPRO.....	SEC 3A.1
APO-LEVOFLOXACIN.....	SEC 3A.6	CIPROFLOXACIN.....	SEC 3A.1
APO-MOXIFLOXACIN.....	SEC 3A.7	CIPROFLOXACIN.....	SEC 3A.2
APO-RIZATRIPTAN.....	SEC 3.6	CIPROFLOXACIN HCL.....	SEC 3A.2
APO-SUMATRIPTAN.....	SEC 3.8	CIPROFLOXACIN HCL.....	SEC 3A.3
ARIPIPRAZOLE.....	4	CLARITIN.....	2
ARIPIPRAZOLE.....	5	CLOTRIMADERM.....	9
AURO-ARIPIPRAZOLE.....	4	CLOTRIMAZOLE.....	10
AURO-ARIPIPRAZOLE.....	5	CLOTRIMAZOLE.....	9
AURO-CIPROFLOXACIN.....	SEC 3A.2	CLOTRIMAZOLE/ CLOTRIMAZOLE.....	10
AURO-MOXIFLOXACIN.....	SEC 3A.7	COLACE.....	8
AURO-RIZATRIPTAN.....	SEC 3.6	COLYTE.....	8
B		COMPLEAT.....	7
BENEPROTEIN.....	SEC 3.5	COMPLEAT PEDIATRIC.....	SEC 3.6
BETA CAROTENE/ BIOTIN/ CALCIUM CARBONATE/ CHROMIUM CHLORIDE/ COPPER CITRATE/ FOLIC ACID/ POTASSIUM IODIDE/ IRON/ MAGNESIUM OXIDE/ MANGANESE/ SODIUM MOLYBDATE/ NIACINAMIDE (NICOTINAMIDE)/ CALCIUM D-PANTOTHENATE/ RIBOFLAVIN (VITAMIN B2)/ SODIUM SELENATE/ THIAMINE MONONITRATE/ VITAMIN A ACETATE/ CYANOCOBALAMIN/ PYRIDOXINE HCL/ ASCORBIC ACID/ VITAMIN D/ VITAMIN E (DL-ALPHA TOCOPHERYL ACETATE)/ ZINC OXIDE.....	12	CONSIST-RITE.....	12
		CROMOLYN.....	7
		CYPROHEPTADINE.....	1
		CYPROHEPTADINE HCL.....	1
		D	
		D-VI-SOL INFANT.....	11
		D3-DOL.....	11
		DESFLORATADINE.....	1
		DEXTROMETHORPHAN HBR/ PSEUDOEPHEDRINE HCL.....	1
		DIABETES SUPPLIES.....	1

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

**ALBERTA HUMAN SERVICES DRUG BENEFIT SUPPLEMENT
APPENDIX 2 – ALPHABETICAL LIST OF PHARMACEUTICAL PRODUCTS**

Product Name	Page	Product Name	Page
DIMENHYDRINATE.....	9	INFUSION SETS (TUBING & NEEDLE)	1
DIMETAPP COLD.....	1	INSTANT FOOD THICKENER.....	12
DIMETHICONE.....	10	INSULIN CARTRIDGES / RESERVOIRS	1
DIPHENHYDRAMINE.....	2	INSULIN PEN NEEDLES.....	1
DIPHENHYDRAMINE HCL.....	2	INSULIN SYRINGES.....	1
DOCUSATE SODIUM.....	8	ISOPROPYL MYRISTATE.....	10
DULCOLAX.....	8	ISOSOURCE 1.0 HP.....	SEC 3.5
DUOCAL.....	SEC 3.5	ISOSOURCE 1.2.....	6
<hr/> E <hr/>		ISOSOURCE 1.5.....	6
ENE-MED.....	9	ISOSOURCE 2.0.....	6
ENFAMIL ENFACARE A+.....	6	ISOSOURCE FIBRE 1.0 HP.....	SEC 3.5
ENSURE.....	SEC 3.5	ISOSOURCE FIBRE 1.2.....	6
ENSURE HIGH-PROTEIN.....	SEC 3.5	ISOSOURCE FIBRE 1.5.....	6
ENSURE PLUS.....	6	<hr/> J <hr/>	
ENSURE REGULAR.....	6	JAMP FERROUS SULFATE.....	3
ENSURE SCFOS FIBRE.....	6	JAMP FERROUS SULFATE INFANT DROPS.....	3
EURO-CYPROHEPTADINE.....	1	JAMP REHYDRALYTE.....	6
EXTRA STRENGTH LACTAID.....	9	JAMP-ACETAMINOPHEN BLAZON.....	3
<hr/> F <hr/>		JAMP-ACETAMINOPHEN EXTRA STRENGTH.....	3
FER-IN-SOL.....	3	JAMP-CIPROFLOXACIN.....	SEC 3A.2
FERODAN.....	3	JAMP-CIPROFLOXACIN.....	SEC 3A.3
FERODAN INFANT.....	3	JAMP-DIMENHYDRINATE.....	9
FERROUS FUMARATE.....	3	JAMP-FERROUS FUMARATE.....	3
FERROUS SULFATE.....	3	JAMP-FLUCONAZOLE.....	2
FLEET ENEMA.....	9	JAMP-LACTASE ENZYME.....	9
FLEET ENEMA PEDIATRIC (65 ML).....	9	JAMP-MOXIFLOXACIN.....	SEC 3A.7
FLINTSTONES MULTI VITAMINS PLUS IRON.....	12	JAMP-RIZATRIPTAN.....	SEC 3.6
FLINTSTONES MULTI VITAMINS W EXTRA C.....	11	JAMP-RIZATRIPTAN IR.....	SEC 3.6
FLUCONAZOLE.....	2	JAMP-RIZATRIPTAN ODT.....	SEC 3.7
<hr/> G <hr/>		JAMP-VITAMIN D.....	11
GASTROLYTE.....	6	JAMP-ZOLMITRIPTAN.....	SEC 3.8
GLUCERNA.....	7	JAMP-ZOLMITRIPTAN ODT.....	SEC 3.8
GLUCOSE CALIBRATION SOLUTION.....	1	JEVITY 1 CAL.....	6
GLYCERIN.....	8	JEVITY 1.2 CAL.....	SEC 3.5
GLYCERIN INFANT.....	8	JEVITY 1.5 CAL.....	SEC 3.5
<hr/> H <hr/>		<hr/> K <hr/>	
HABITROL 14 MG/DAY.....	2	KETOCAL.....	SEC 3.6
HABITROL 21 MG/DAY.....	2	KETOVIE 3:1.....	SEC 3.6
HABITROL 7 MG/DAY.....	2	KETOVIE 4:1.....	SEC 3.6
<hr/> I <hr/>		KETOVIE PEPTIDE 4:1.....	SEC 3.6
IBUPROFEN.....	3	KWELLADA-P.....	10
IMITREX.....	SEC 3.7	KWELLADA-P CREME.....	10
IMITREX (0.5 ML).....	SEC 3.8	<hr/> L <hr/>	
IMITREX DF.....	SEC 3.8	LACTAID.....	9
IMODIUM.....	8	LACTAID ULTRA (CAPLET).....	9
INFANT FORMULA.....	6	LACTASE.....	9
INFANT FORMULA.....	SEC 3.4	LANCING DEVICE.....	1
		LEVOFLOXACIN.....	SEC 3A.4
		LEVOFLOXACIN.....	SEC 3A.5
		LEVOFLOXACIN.....	SEC 3A.6
		LOPERAMIDE HCL.....	8
		LORATADINE.....	2

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

ALBERTA HUMAN SERVICES DRUG BENEFIT SUPPLEMENT
APPENDIX 2 – ALPHABETICAL LIST OF PHARMACEUTICAL PRODUCTS

Product Name	Page	Product Name	Page
<hr/> M <hr/>			
MAR-CIPROFLOXACIN.....	SEC 3A.2	NUTRITIONAL PRODUCT (PEDIATRIC)	SEC 3.6
MAR-CIPROFLOXACIN.....	SEC 3A.2	NUTRITIONAL PRODUCT (RENAL).....	7
MAR-CIPROFLOXACIN.....	SEC 3A.3	NUTRITIONAL PRODUCTS.....	SEC 3.6
MAR-FLUCONAZOLE-150	2	NYADERM.....	10
MAR-MOXIFLOXACIN	SEC 3A.7	NYDA	10
MAR-RIZATRIPTAN	SEC 3.6	NYSTATIN.....	10
MAR-RIZATRIPTAN ODT	SEC 3.7	<hr/> O <hr/>	
MAXALT.....	SEC 3.6	OPTICROM	7
MAXALT RPD	SEC 3.7	<hr/> P <hr/>	
MCT OIL	SEC 3.5	PALAFER.....	3
MED-MOXIFLOXACIN	SEC 3A.7	PEDIALYTE (FLAVOURED).....	6
MICONAZOLE NITRATE	10	PEDIALYTE (UNFLAVOURED)	6
MICOZOLE	10	PEDIASURE	7
MINT-CIPROFLOX	SEC 3A.2	PEDIASURE FIBRE	7
MINT-CIPROFLOX	SEC 3A.3	PEDIASURE PEPTIDE 1 CAL.....	7
MINT-ZOLMITRIPTAN.....	SEC 3.8	PEDIASURE PLUS WITH FIBRE.....	SEC 3.6
MODULEN IBD	SEC 3.6	PEDIATRIC ELECTROLYTE.....	6
MOXIFLOXACIN HCL.....	SEC 3A.7	PEDIATRIX.....	3
MYLAN-ALMOTRIPTAN	SEC 3.4	PEDIATRIX.....	4
MYLAN-RIZATRIPTAN ODT.....	SEC 3.7	PEG-LYTE.....	8
MYLAN-SUMATRIPTAN.....	SEC 3.8	PEPTAMEN.....	SEC 3.5
<hr/> N <hr/>		PEPTAMEN 1.5.....	SEC 3.5
NARATRIPTAN HCL.....	SEC 3.4	PEPTAMEN AF 1.2	SEC 3.5
NAT-RIZATRIPTAN ODT.....	SEC 3.7	PEPTAMEN JUNIOR	SEC 3.6
NAT-ZOLMITRIPTAN	SEC 3.8	PEPTAMEN JUNIOR 1.5	SEC 3.6
NEOCATE JUNIOR	SEC 3.6	PEPTAMEN WITH PREBIO 1	SEC 3.5
NEOCATE JUNIOR WITH FIBRE.....	SEC 3.6	PERMETHRIN.....	10
NEOCATE SPLASH.....	SEC 3.6	PMS-ARIPIPRAZOLE	4
NEOCATE WITH DHA & ARA	SEC 3.4	PMS-ARIPIPRAZOLE	5
NEPRO	7	PMS-CIPROFLOXACIN	SEC 3A.2
NESTLE MATERNA.....	12	PMS-CIPROFLOXACIN	SEC 3A.3
NICODERM 14 MG/DAY	2	PMS-LOPERAMIDE (CAPLET).....	8
NICODERM 21 MG/DAY	2	PMS-RIZATRIPTAN RDT.....	SEC 3.7
NICODERM 7 MG/DAY	2	PMS-SUMATRIPTAN	SEC 3.8
NICORETTE	2	PMS-ZOLMITRIPTAN	SEC 3.8
NICORETTE INHALER.....	2	POLY-VI-SOL	11
NICORETTE QUICKMIST	2	POLYETHYLENE GLYCOL/ POTASSIUM CHLORIDE (K+)/ SODIUM SULFATE/ SODIUM CHLORIDE/ SODIUM BICARBONATE	8
NICOTINE	2	POLYETHYLENE GLYCOL/ SODIUM SULFATE/ SODIUM BICARBONATE/ SODIUM CHLORIDE/ POTASSIUM CHLORIDE (K+).....	8
NIX CREME	10	PURAMINO A+.....	SEC 3.4
NIX DERMAL	10	PURAMINO A+ JUNIOR	SEC 3.6
NOVASOURCE RENAL.....	7	PYRETHRINS/ PIPERONYL BUTOXIDE.....	11
NOVO GESIC FORTE	3	<hr/> R <hr/>	
NUTRAMIGEN A+ HYPOALLERGENIC.....	6	R & C SHAMPOO WITH CONDITIONER	11
NUTREN JUNIOR.....	7	RAN-CIPROFLOX	SEC 3A.2
NUTREN JUNIOR FIBRE W PREBIO 1	7	RAN-CIPROFLOX.....	SEC 3A.3
NUTRITIONAL PRODUCT	6	RATIO-DOCUSATE SODIUM	8
NUTRITIONAL PRODUCT	SEC 3.5	RESOURCE 2.0	6
NUTRITIONAL PRODUCT (ADULT MEAL REPLACEMENT)	6	RESOURCE DIABETIC.....	7
NUTRITIONAL PRODUCT (ADULT MEAL REPLACEMENT)	SEC 3.5		
NUTRITIONAL PRODUCT (ADULT)	7		
NUTRITIONAL PRODUCT (ADULT)	SEC 3.5		
NUTRITIONAL PRODUCT (DIABETIC).....	7		
NUTRITIONAL PRODUCT (PEDIATRIC).....	7		

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

ALBERTA HUMAN SERVICES DRUG BENEFIT SUPPLEMENT
APPENDIX 2 – ALPHABETICAL LIST OF PHARMACEUTICAL PRODUCTS

Product Name	Page	Product Name	Page
RESOURCE KID ESSENTIALS 1.5 CAL.....	7	TEVA-SUMATRIPTAN	SEC 3.8
RESOURCE THICKENUP	12	TEVA-SUMATRIPTAN DF	SEC 3.8
RESOURCE THICKENUP CLEAR	12	TEVA-ZOLMITRIPTAN.....	SEC 3.8
RESULTZ.....	10	THE MAGIC BULLET	8
RIZATRIPTAN BENZOATE	SEC 3.6	TOLEREX.....	SEC 3.5
RIZATRIPTAN BENZOATE	SEC 3.7	TRANSDERMAL NICOTINE 14 MG/DAY	2
RIZATRIPTAN ODT.....	SEC 3.7	TRANSDERMAL NICOTINE 21 MG/DAY	2
ROBITUSSIN CHILDRENS COUGH AND COLD.....	1	TRANSDERMAL NICOTINE 7 MG/DAY	2
<hr/> S <hr/>			
SALINEX.....	7	TRI-VI-SOL.....	11
SANDOZ ALMOTRIPTAN.....	SEC 3.4	TWOCAL HN.....	SEC 3.5
SANDOZ ARIPIPRAZOLE	4	TYLENOL EXTRA STRENGTH.....	3
SANDOZ ARIPIPRAZOLE	5	TYLENOL EXTRA-STRENGTH (CAPLET).....	3
SANDOZ CIPROFLOXACIN.....	SEC 3A.2	<hr/> U <hr/>	
SANDOZ CIPROFLOXACIN.....	SEC 3A.3	URINE TEST STRIPS	1
SANDOZ DIMENHYDRINATE.....	9	<hr/> V <hr/>	
SANDOZ LEVOFLOXACIN.....	SEC 3A.4	VITAL PEPTIDE 1 CAL	7
SANDOZ LEVOFLOXACIN.....	SEC 3A.5	VITAL PEPTIDE 1.5 CAL	7
SANDOZ LEVOFLOXACIN.....	SEC 3A.6	VITAMIN A ACETATE/ THIAMINE MONONITRATE/ RIBOFLAVIN (VITAMIN B2)/ PYRIDOXINE HCL/ CYANOCOBALAMIN/ SODIUM ASCORBATE/ VITAMIN D/ FOLIC ACID/ NIACINAMIDE (NICOTINAMIDE).....	11
SANDOZ MOXIFLOXACIN	SEC 3A.7	VITAMIN A ACETATE/ THIAMINE MONONITRATE/ RIBOFLAVIN (VITAMIN B2)/ PYRIDOXINE HCL/ CYANOCOBALAMIN/ SODIUM ASCORBATE/ VITAMIN D/ FOLIC ACID/ NIACINAMIDE (NICOTINAMIDE)/ FERROUS FUMARATE.....	12
SANDOZ NARATRIPTAN.....	SEC 3.4	VITAMIN A PALMITATE/ VITAMIN D/ ASCORBIC ACID	11
SANDOZ RIZATRIPTAN ODT	SEC 3.7	VITAMIN A PALMITATE/ VITAMIN D/ SODIUM ASCORBATE/ THIAMINE HCL/ RIBOFLAVIN (VITAMIN B2)/ NIACINAMIDE (NICOTINAMIDE) ...	11
SANDOZ SUMATRIPTAN	SEC 3.8	VITAMIN D3	11
SANDOZ ZOLMITRIPTAN.....	SEC 3.8	VIVONEX PEDIATRIC	SEC 3.6
SCANDISHAKE	SEC 3.5	VIVONEX PLUS	SEC 3.5
SEPTA-ZOLMITRIPTAN-ODT	SEC 3.8	VIVONEX T.E.N.	SEC 3.5
SIMILAC ALIMENTUM.....	6	<hr/> Z <hr/>	
SIMILAC NEOSURE.....	6	ZOLMITRIPTAN	SEC 3.8
SODIUM CHLORIDE	7	ZOMIG.....	SEC 3.8
SODIUM CHLORIDE/ POTASSIUM CHLORIDE (K+)(CL-)/ SODIUM CITRATE,ACID/ DEXTROSE ...	6	ZOMIG RAPIMELT	SEC 3.8
SODIUM CHLORIDE/ SODIUM CITRATE,ACID/ DEXTROSE/ POTASSIUM CITRATE (K+)	6	ZYBAN	2
SODIUM CROMOGLYCATE	7		
SODIUM PHOSPHATE/ SODIUM ACID PHOSPHATE	9		
SODIUM/ POTASSIUM/ CHLORIDE/ CITRATE/ DEXTROSE	6		
SODIUM/ POTASSIUM/ CHLORIDE/ CITRATE/ ZINC/ DEXTROSE	6		
SUMATRIPTAN	SEC 3.8		
SUMATRIPTAN DF.....	SEC 3.8		
SUMATRIPTAN HEMISULFATE	SEC 3.7		
SUMATRIPTAN SUCCINATE.....	SEC 3.8		
SUPLENA	7		
<hr/> T <hr/>			
TARO-SUMATRIPTAN (0.5 ML).....	SEC 3.8		
TEMPRA D.S.	4		
TEVA-ALMOTRIPTAN	SEC 3.4		
TEVA-ARIPIPRAZOLE	4		
TEVA-ARIPIPRAZOLE	5		
TEVA-LOPERAMIDE (CAPLET).....	8		
TEVA-MOXIFLOXACIN	SEC 3A.7		
TEVA-NARATRIPTAN	SEC 3.4		
TEVA-RIZATRIPTAN ODT	SEC 3.7		

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

Appendix 3

Drug Identification Numbers of Pharmaceutical Products

DIN	Page	DIN	Page	DIN	Page	DIN	Page
0000003875.....	8	0000999430...SEC 3.5		0000999942.....	1	00002231480.....	10
0000009911.....	9	0000999434...SEC 3.6		0000999944...SEC 3.5		00002231507.....	9
0000017884.....	3	0000999435...SEC 3.5		0000999952.....	1	00002232297.....	3
00000108065.....	9	0000999440...SEC 3.5		0000999955.....	1	00002237385.....	3
00000254142.....	8	0000999444...SEC 3.5		0000999957.....	1	00002237514 SEC 3A.1	
00000392545.....	9	0000999445...SEC 3.6		0000999966.....	7	00002237820.. SEC 3.4	
00000392553.....	9	0000999447...SEC 3.6		0000999983...SEC 3.5		00002237821.. SEC 3.4	
00000482323.....	3	0000999449.....	6	0000999985.....	1	00002238441.....	2
00000545007.....	3	0000999453.....	12	00001923439.....	3	00002238660.. SEC 3.8	
00000559407.....	3	0000999455.....	12	00001931563.....	6	00002239139.....	9
00000677442.....	8	0000999458.....	7	00001939122.....	3	00002239367.. SEC 3.8	
00000716871.....	10	0000999465.....	6	00001943057.....	2	00002239432.....	9
00000723908.....	3	0000999467...SEC 3.5		00001943065.....	2	00002240518.. SEC 3.7	
00000758469.....	3	0000999475...SEC 3.5		00001943073.....	2	00002240519.. SEC 3.7	
00000762881.....	11	0000999483.....	7	00002009277.....	7	00002240521.. SEC 3.6	
00000762903.....	11	0000999520.....	6	00002020815.....	8	00002241091.....	8
00000762946.....	11	0000999525.....	6	00002027798.....	3	00002241226.....	2
00000762954.....	3	0000999543...SEC 3.4		00002027801.....	4	00002241227.....	2
00000771368.....	10	0000999545.....	7	00002044013.....	1	00002241228.....	2
00000777838.....	8	0000999553...SEC 3.6		00002086018.....	8	00002241523.....	2
00000812366.....	9	0000999559...SEC 3.6		00002090163.....	8	00002241742.....	2
00000812374.....	9	0000999560...SEC 3.6		00002091933.....	2	00002241895.....	2
00000870226.....	8	0000999561.....	12	00002091941.....	2	00002242365.....	3
00000875996.....	4	0000999564.....	6	00002093111.....	2	00002243045.. SEC 3.8	
00000884553.....	3	0000999565...SEC 3.6		00002093138.....	2	00002243980.....	1
00000989996.....	7	0000999568...SEC 3.4		00002093146.....	2	00002245416.....	9
00000989997.....	7	0000999788.....	6	00002125447.....	11	00002245667.....	1
00000989998.....	7	0000999864...SEC 3.6		00002132591.....	8	00002247193.....	1
00000990024.....	1	0000999865...SEC 3.6		00002150883.....	10	00002247339 SEC 3A.2	
00000990029.....	7	0000999866...SEC 3.6		00002150891.....	9	00002247340 SEC 3A.2	
00000990045.....	1	0000999876...SEC 3.6		00002150905.....	9	00002247341 SEC 3A.3	
00000990056.....	7	0000999886...SEC 3.5		00002212153...SEC 3.8		00002247975.....	11
00000990057.....	1	0000999888.....	6	00002212161...SEC 3.8		00002247995.....	12
00000990058.....	1	0000999889.....	6	00002212188...SEC 3.8		00002248437 SEC 3A.2	
00000999391...SEC 3.6		0000999890...SEC 3.5		00002219883.....	6	00002248438 SEC 3A.2	
00000999402...SEC 3.5		0000999895.....	6	00002219905.....	10	00002248439 SEC 3A.3	
00000999404...SEC 3.5		0000999896.....	6	00002228351.....	8	00002248756 SEC 3A.2	
00000999405...SEC 3.5		0000999901.....	6	00002229977.....	3	00002248757 SEC 3A.2	
00000999408...SEC 3.6		0000999902.....	6	00002230418...SEC 3.7		00002248758 SEC 3A.3	
00000999409.....	6	0000999920.....	6	00002230420...SEC 3.7		00002248993.. SEC 3.8	
00000999413.....	7	0000999921.....	6	00002230434.....	4	00002252813.....	3
00000999414.....	7	0000999927...SEC 3.5		00002230436.....	4	00002256436.. SEC 3.8	
00000999415...SEC 3.5		0000999929...SEC 3.5		00002230437.....	4	00002256444.. SEC 3.8	
00000999416...SEC 3.5		0000999932.....	6	00002230509.....	10	00002263025.. SEC 3.8	
00000999418.....	7	0000999933.....	7	00002230621.....	7	00002263033.. SEC 3.8	
00000999419.....	7	0000999934...SEC 3.5		00002230653.....	9	00002264099.....	10
00000999421...SEC 3.5		0000999935...SEC 3.5		00002230654.....	9	00002264102.....	10
00000999422...SEC 3.6		0000999938.....	6	00002231106.....	10	00002268388.. SEC 3.8	
00000999426...SEC 3.6		0000999940.....	7	00002231170.....	9	00002268396.. SEC 3.8	
00000999427...SEC 3.5		0000999941.....	1	00002231348.....	10	00002268914.. SEC 3.8	

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

**ALBERTA HUMAN SERVICES DRUG BENEFIT SUPPLEMENT
APPENDIX 3 – NUMERICAL LIST BY DRUG IDENTIFICATION NUMBER**

DIN	Page	DIN	Page	DIN	Page	DIN	Page
00002268922...SEC 3.8		00002380455...SEC 3.6		00002460068..... 5			
00002279592..... 10		00002380463...SEC 3.6		00002460076..... 5			
00002284707 SEC 3A.4		00002381702...SEC 3.6		00002460084..... 5			
00002284715 SEC 3A.5		00002381907 SEC 3A.2		00002462788...SEC 3.7			
00002286521...SEC 3.8		00002381923 SEC 3A.2		00002462796...SEC 3.7			
00002286548...SEC 3.8		00002383381 SEC 3A.7		00002464144..... 4			
00002286823...SEC 3.8		00002385570...SEC 3.8		00002464160..... 5			
00002286831...SEC 3.8		00002385589...SEC 3.8		00002464179..... 5			
00002291800..... 8		00002386119 SEC 3A.2		00002464187..... 5			
00002298503..... 2		00002386127 SEC 3A.2		00002464195..... 5			
00002298635 SEC 3A.4		00002393360...SEC 3.7		00002465086...SEC 3.7			
00002298643 SEC 3A.5		00002393379...SEC 3.7		00002465094...SEC 3.7			
00002298651 SEC 3A.6		00002393468...SEC 3.6		00002466635..... 4			
00002303728 SEC 3A.2		00002393476...SEC 3.6		00002466643..... 4			
00002303736 SEC 3A.2		00002396661...SEC 3.7		00002466651..... 5			
00002303744 SEC 3A.3		00002396688...SEC 3.7		00002466678..... 5			
00002313960...SEC 3.8		00002398435...SEC 3.4		00002466686..... 5			
00002314290...SEC 3.4		00002398443...SEC 3.4		00002466694..... 5			
00002314304...SEC 3.4		00002404923 SEC 3A.7		00002466821...SEC 3.4			
00002315424 SEC 3A.4		00002405334...SEC 3.4		00002471086..... 4			
00002315432 SEC 3A.5		00002419521...SEC 3.8		00002471094..... 4			
00002315440 SEC 3A.6		00002421534...SEC 3.8		00002471108..... 5			
00002322323...SEC 3.4		00002421623...SEC 3.8		00002471116..... 5			
00002322374..... 4		00002423553 SEC 3A.2		00002471124..... 5			
00002322382..... 4		00002423588 SEC 3A.3		00002471132..... 5			
00002322390..... 5		00002428237...SEC 3.8		00002473658..... 4			
00002322404..... 5		00002428474...SEC 3.8		00002473666..... 4			
00002322412..... 5		00002428792..... 2		00002473674..... 5			
00002322455..... 5		00002429233...SEC 3.6		00002473682..... 5			
00002324229...SEC 3.8		00002429241...SEC 3.6		00002473690..... 5			
00002325942 SEC 3A.6		00002432242 SEC 3A.7		00002473704..... 5			
00002332248..... 1		00002432471..... 2		00002483270...SEC 3.7			
00002351870...SEC 3.7		00002434849...SEC 3.4		00002483289...SEC 3.7			
00002351889...SEC 3.7		00002436604...SEC 3.7		00009998877..... 6			
00002353318 SEC 3A.2		00002436612...SEC 3.7		00080003038..... 11			
00002353326 SEC 3A.2		00002441144...SEC 3.6		00080008295..... 3			
00002355299..... 3		00002442906...SEC 3.7		00080008309..... 3			
00002361698...SEC 3.8		00002442914...SEC 3.7		00080018706..... 9			
00002362988...SEC 3.8		00002443929 SEC 3A.7		00080019649..... 11			
00002373785..... 10		00002446111...SEC 3.7		00080024901..... 7			
00002375702 SEC 3A.7		00002446138...SEC 3.7		00080027403..... 6			
00002379198...SEC 3.7		00002447053 SEC 3A.7		00080029822..... 3			
00002379201...SEC 3.7		00002447061 SEC 3A.7		00080038858..... 2			
00002379678...SEC 3.6		00002457814 SEC 3A.7		00080070358..... 9			
00002379686 SEC 3A.2		00002458764...SEC 3.7		00080072902..... 6			
00002379694 SEC 3A.2		00002458772...SEC 3.7		00080074173..... 6			
00002379708 SEC 3A.3		00002458780...SEC 3.8		00080082297..... 12			
00002380358 SEC 3A.2		00002460025..... 4					
00002380366 SEC 3A.2		00002460033..... 4					
00002380374 SEC 3A.3		00002460041..... 5					

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.